[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2086
1. Giaginis C, Davides D, Zarros A, Noussia O, Zizi-Serbetzoglou A, Kouraklis G, Theocharis S: Clinical significance of tumor-associated antigen RCAS1 expression in human pancreatic ductal adenocarcinoma. Dig Dis Sci; 2008 Jun;53(6):1728-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of tumor-associated antigen RCAS1 expression in human pancreatic ductal adenocarcinoma.
  • The aim of the present study was to evaluate the clinical significance of RCAS1 expression in human pancreatic adenocarcinoma.
  • Immunohistochemical analysis of RCAS1 expression was performed on paraffin-embedded tissue sections obtained from 76 pancreatic adenocarcinoma patients.
  • Of the 76 adenocarcinoma patients, 65 (86%) tested positive for RCAS1; of these 65 RCAS1-positive cases, 36 (55%) showed RCAS1 overexpression.
  • Our data provide evidence for the implication of RCAS1 in pancreatic neoplasia.
  • [MeSH-major] Adenocarcinoma / metabolism. Antigens, Neoplasm / metabolism. Carcinoma, Pancreatic Ductal / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2001 Jul 15;98(2):313-21 [11435298.001]
  • [Cites] Oncol Rep. 2007 Mar;17(3):623-8 [17273743.001]
  • [Cites] Ann Surg Oncol. 2002 May;9(4):388-93 [11986191.001]
  • [Cites] Int J Cancer. 2002 May 20;99(3):418-23 [11992411.001]
  • [Cites] Pancreas. 2003 Jan;26(1):49-55 [12499917.001]
  • [Cites] Dis Colon Rectum. 2007 Aug;50(8):1241-9 [17429708.001]
  • [Cites] Oncol Rep. 2005 Nov;14(5):1127-32 [16211275.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):411-6 [16428480.001]
  • [Cites] Nucleic Acids Res. 1988 Aug 25;16(16):7773-82 [3047672.001]
  • [Cites] Pancreatology. 2006;6(4):268-72 [16636598.001]
  • [Cites] Neuro Endocrinol Lett. 2006 Dec;27(6):786-94 [17187007.001]
  • [Cites] Mod Pathol. 2003 Jul;16(7):679-85 [12861064.001]
  • [Cites] J Gastroenterol Hepatol. 2005 Aug;20(8):1143-8 [16048560.001]
  • [Cites] Int J Cancer. 2000 Nov 20;89(6):488-93 [11102892.001]
  • [Cites] Int J Oncol. 2001 Oct;19(4):695-700 [11562743.001]
  • [Cites] Cancer Lett. 2007 Feb 8;246(1-2):182-9 [16595162.001]
  • [Cites] Dig Dis Sci. 2004 Oct;49(10 ):1654-6 [15573922.001]
  • [Cites] Gynecol Oncol. 2000 Dec;79(3):424-9 [11104614.001]
  • [Cites] Gynecol Oncol. 2005 Oct;99(1):189-98 [16112176.001]
  • [Cites] Postgrad Med J. 1997 Sep;73(863):543-8 [9373592.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):565-76 [12842085.001]
  • [Cites] Dig Dis Sci. 2007 Feb;52(2):549-54 [17211709.001]
  • [Cites] Cancer Lett. 2001 Jul 26;168(2):197-202 [11403925.001]
  • [Cites] J Dermatol Sci. 2001 Jun;26(2):140-4 [11378331.001]
  • [Cites] Int J Oncol. 2006 Jul;29(1):65-72 [16773186.001]
  • [Cites] World J Gastroenterol. 2005 Sep 7;11(33):5199-202 [16127752.001]
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2527-30 [8653691.001]
  • [Cites] Clin Cancer Res. 1999 Jun;5(6):1449-53 [10389931.001]
  • [Cites] Nat Med. 1999 Aug;5(8):938-42 [10426319.001]
  • [Cites] Br J Cancer. 2001 Dec 14;85(12):1922-7 [11747335.001]
  • [Cites] Cancer. 2001 Jul 15;92(2):446-51 [11466701.001]
  • [Cites] Cancer. 1996 Apr 15;77(8):1501-9 [8608535.001]
  • (PMID = 17932753.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / EBAG9 protein, human
  •  go-up   go-down


2. Pakzad F, Groves AM, Ell PJ: The role of positron emission tomography in the management of pancreatic cancer. Semin Nucl Med; 2006 Jul;36(3):248-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of positron emission tomography in the management of pancreatic cancer.
  • The role of positron emission tomography (PET) and PET/computed tomography (CT) in the assessment of a patient presenting with cancer of the pancreas is discussed in the overall context of the management of this condition.
  • Overall detection sensitivity at diagnosis varies between 90% and 95% and specificity from 82% to 100%, whereas for staging, sensitivity data vary from 61% to 100% and specificity data from 67% to 100%.
  • [MeSH-major] Pancreatic Neoplasms / radionuclide imaging. Positron-Emission Tomography
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / radiography. Adenocarcinoma / radionuclide imaging. Adenocarcinoma / secondary. Adenocarcinoma / ultrasonography. Adult. Case Management. Female. Fluorodeoxyglucose F18. Humans. Lymphatic Metastasis / radionuclide imaging. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiopharmaceuticals. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16762614.001).
  • [ISSN] 0001-2998
  • [Journal-full-title] Seminars in nuclear medicine
  • [ISO-abbreviation] Semin Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 52
  •  go-up   go-down


3. Gahr S, Ocker M, Ganslmayer M, Zopf S, Okamoto K, Hartl A, Leitner S, Hahn EG, Herold C: The combination of the histone-deacetylase inhibitor trichostatin A and gemcitabine induces inhibition of proliferation and increased apoptosis in pancreatic carcinoma cells. Int J Oncol; 2007 Sep;31(3):567-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The combination of the histone-deacetylase inhibitor trichostatin A and gemcitabine induces inhibition of proliferation and increased apoptosis in pancreatic carcinoma cells.
  • The prognosis of advanced pancreatic cancer is poor.
  • We investigated how far a combination of trichostatin A (TSA) and gemcitabine synergizes to inhibit proliferation and promotion of apoptosis of pancreatic adenocarcinoma cells in vitro.
  • The human pancreatic carcinoma cells YAPC, DANG and Panc-89 and primary human foreskin fibroblasts as non-malignant controls were cultured under standardized conditions and incubated with gemcitabine und TSA alone (10(-4) to 10(-8) M) or together (10(-6) to 10(-7) M).
  • Combination of TSA and gemcitabine shows promise for treatment of pancreatic cancer in vivo.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Apoptosis / drug effects. Carcinoma / drug therapy. Cell Proliferation / drug effects. Deoxycytidine / analogs & derivatives. Hydroxamic Acids / administration & dosage. Pancreatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17671683.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Hydroxamic Acids; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-2-Associated X Protein; 0W860991D6 / Deoxycytidine; 3X2S926L3Z / trichostatin A; B76N6SBZ8R / gemcitabine; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 8; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras)
  •  go-up   go-down


Advertisement
4. Chang CL, Wu TC, Hung CF: Control of human mesothelin-expressing tumors by DNA vaccines. Gene Ther; 2007 Aug;14(16):1189-98
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mesothelin has been implicated as a potential ideal target antigen for the development of antigen-specific cancer immunotherapy for the control of mesothelin-expressing cancers such as ovarian cancer, mesothelioma and pancreatic adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Feb 15;60(4):1035-42 [10706121.001]
  • [Cites] Gene Ther. 2007 Jan;14(1):20-9 [16915291.001]
  • [Cites] CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33 [10735013.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 May 9;97(10):5492-7 [10779556.001]
  • [Cites] Surgery. 2000 Aug;128(2):273-80 [10923004.001]
  • [Cites] J Leukoc Biol. 2000 Dec;68(6):793-806 [11129646.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):859-63 [11221870.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11545-50 [11553767.001]
  • [Cites] Vaccine. 2001 Nov 12;20(3-4):421-9 [11672905.001]
  • [Cites] Cancer Immunol Immunother. 2001 Sep;50(7):356-60 [11676395.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):3862-8 [11751476.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1):41-50 [11836668.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1):82-96 [11836673.001]
  • [Cites] Anticancer Res. 2001 Sep-Oct;21(5):3677-84 [11848542.001]
  • [Cites] Gene Ther. 2002 Feb;9(3):208-13 [11859424.001]
  • [Cites] Immunology. 2002 Sep;107(1):39-45 [12225361.001]
  • [Cites] Front Biosci. 2003 Jan 1;8:d55-68 [12456324.001]
  • [Cites] Nat Med. 2002 Dec;8(12):1369-75 [12415261.001]
  • [Cites] Nat Med. 2003 Jan;9(1):33-9 [12496961.001]
  • [Cites] Cancer Res. 2003 Feb 1;63(3):600-7 [12566302.001]
  • [Cites] J Immunol. 2003 Mar 15;170(6):3162-70 [12626574.001]
  • [Cites] Curr Opin Mol Ther. 2003 Feb;5(1):20-4 [12669466.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8850-5 [12857959.001]
  • [Cites] Int J Cancer. 2003 Dec 20;107(6):976-83 [14601058.001]
  • [Cites] Lancet. 2003 Nov 15;362(9396):1612-6 [14630441.001]
  • [Cites] IDrugs. 2003 Dec;6(12):1155-64 [14666426.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):3937-42 [15217923.001]
  • [Cites] Nat Med. 2004 Sep;10(9):950-8 [15334073.001]
  • [Cites] Immunity. 1995 Aug;3(2):165-9 [7648389.001]
  • [Cites] Annu Rev Immunol. 1997;15:617-48 [9143702.001]
  • [Cites] J Clin Invest. 1998 Sep 15;102(6):1258-64 [9739060.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11531-6 [10500211.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3814-20 [15897581.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):827-31 [16467095.001]
  • [Cites] Am J Clin Pathol. 2006 Oct;126(4):572-9 [17019794.001]
  • [Cites] Vaccine. 2007 Jan 2;25(1):127-35 [16930783.001]
  • [Cites] Int J Cancer. 2000 Apr 1;86(1):89-94 [10728600.001]
  • (PMID = 17581599.001).
  • [ISSN] 0969-7128
  • [Journal-full-title] Gene therapy
  • [ISO-abbreviation] Gene Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U19 CA113341; United States / NCI NIH HHS / CA / 1U19 CA113341-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Cancer Vaccines; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / Vaccines, DNA; 0 / mesothelin
  • [Other-IDs] NLM/ NIHMS321551; NLM/ PMC3182456
  •  go-up   go-down


5. Lee J, Jang KT, Ki CS, Lim T, Park YS, Lim HY, Choi DW, Kang WK, Park K, Park JO: Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. Cancer; 2007 Apr 15;109(8):1561-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma.
  • BACKGROUND: Erlotinib, in combination with gemcitabine, has shown clinical benefits in pancreatic adenocarcinoma patients.
  • The presence of EGFR mutations and increased EGFR copy numbers in pancreatic adenocarcinoma was explored.
  • METHODS: Sixty-six pancreatic cancer patients were included in the analysis.
  • RESULTS: In the current study the EGFR mutation was harbored in only 1 (1.5%) of the 66 inoperable or metastatic pancreatic adenocarcinoma patients.
  • There was only 1 patient, who had a highly increased EGFR copy number (> or =6.0 per cell), who died, 2.1 months from the date of diagnosis.
  • The EGFR amplification did not significantly influence survival in pancreatic adenocarcinoma patients (P = .935).
  • Thirty-two (49%) of the 65 pancreatic adenocarcinomas examined harbored a point mutation in codons 12 (n = 31) and 61 (n = 1) of the KRAS gene.
  • The presence of a point mutation in codon 12 adversely influenced survival of pancreatic cancer patients (P = .030).
  • [MeSH-major] Adenocarcinoma / genetics. Genes, ras. Pancreatic Neoplasms / genetics. Receptor, Epidermal Growth Factor / genetics


6. Ryu JK, Hong SM, Karikari CA, Hruban RH, Goggins MG, Maitra A: Aberrant MicroRNA-155 expression is an early event in the multistep progression of pancreatic adenocarcinoma. Pancreatology; 2010;10(1):66-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant MicroRNA-155 expression is an early event in the multistep progression of pancreatic adenocarcinoma.
  • BACKGROUND/AIMS: Pancreatic intraepithelial neoplasia (PanIN) is the most common noninvasive precursor to invasive pancreatic adenocarcinoma.
  • METHODS: Three candidate miRNAs (miR-21, miR-155, and miR-221) previously reported as overexpressed in pancreatic cancers were assessed in 31 microdissected PanINs (14 PanIN-1, 9 PanIN-2, 8 PanIN-3) using quantitative reverse transcription PCR (qRT-PCR).
  • CONCLUSIONS: Abnormalities of miRNA expression are observed in the multistep progression of pancreatic cancer, with miR-155 aberrations demonstrable at the stage of PanIN-2, and miR-21 abnormalities at the stage of PanIN-3 lesions. and IAP.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 2008 Jan;40(1):43-50 [18066065.001]
  • [Cites] Mol Cell Biol. 2008 Nov;28(22):6773-84 [18794355.001]
  • [Cites] JAMA. 2008 Jan 30;299(4):425-36 [18230780.001]
  • [Cites] J Mol Diagn. 2008 Mar;10(2):111-22 [18258927.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Nat Cell Biol. 2008 May;10(5):593-601 [18376396.001]
  • [Cites] J Biol Chem. 2008 May 30;283(22):14910-4 [18411277.001]
  • [Cites] PLoS One. 2008;3(7):e2557 [18596939.001]
  • [Cites] Oncogene. 2008 Jul 17;27(31):4373-9 [18372920.001]
  • [Cites] J Gastrointest Surg. 2008 Dec;12(12):2171-6 [18642050.001]
  • [Cites] World J Surg. 2009 Apr;33(4):698-709 [19030927.001]
  • [Cites] Br J Cancer. 2009 Mar 24;100(6):1002-11 [19293812.001]
  • [Cites] Cancer Biol Ther. 2009 Feb;8(4):340-6 [19106647.001]
  • [Cites] Pancreatology. 2009;9(1-2):66-72 [19077456.001]
  • [Cites] J Cell Mol Med. 2009 Sep;13(9B):3918-28 [19228262.001]
  • [Cites] Am J Pathol. 2000 May;156(5):1767-71 [10793087.001]
  • [Cites] J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79 [11307091.001]
  • [Cites] Am J Surg Pathol. 2001 May;25(5):579-86 [11342768.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Am J Pathol. 2002 Nov;161(5):1541-7 [12414502.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9 [12434020.001]
  • [Cites] Mod Pathol. 2003 Sep;16(9):902-12 [13679454.001]
  • [Cites] Nat Rev Genet. 2004 Jul;5(7):522-31 [15211354.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Jul;2(7):606-21 [15224285.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):977-87 [15252303.001]
  • [Cites] Cancer Res. 1997 Jun 1;57(11):2140-3 [9187111.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3627-32 [15738415.001]
  • [Cites] Oncology (Williston Park). 2005 Mar;19(3):393-404, 409; discussion 409-10, 412-6 [15828554.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):839-43 [15944709.001]
  • [Cites] Mod Pathol. 2005 Jul;18(7):959-63 [15832197.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7065-70 [16103053.001]
  • [Cites] J Pathol. 2005 Oct;207(2):243-9 [16041695.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9628-32 [16266980.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61 [16461460.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):189-98 [16530703.001]
  • [Cites] Cancer Cell. 2006 Jun;9(6):435-43 [16766263.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Jun;4(6):766-81; quiz 665 [16682259.001]
  • [Cites] Am J Surg Pathol. 2006 Sep;30(9):1067-76 [16931950.001]
  • [Cites] Dev Biol. 2007 Feb 1;302(1):1-12 [16989803.001]
  • [Cites] Int J Cancer. 2007 Mar 1;120(5):1046-54 [17149698.001]
  • [Cites] Cancer Res. 2007 Feb 15;67(4):1419-23 [17308078.001]
  • [Cites] Leuk Lymphoma. 2007 Feb;48(2):410-2 [17325905.001]
  • [Cites] Mod Pathol. 2007 May;20(5):570-8 [17396143.001]
  • [Cites] JAMA. 2007 May 2;297(17):1901-8 [17473300.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2007;14(3):224-32 [17520196.001]
  • [Cites] Mol Cell. 2007 Jun 8;26(5):745-52 [17540599.001]
  • [Cites] Oncogene. 2007 Jun 28;26(30):4442-52 [17237814.001]
  • [Cites] Semin Oncol. 2007 Aug;34(4):303-10 [17674958.001]
  • [Cites] Histopathology. 2007 Oct;51(4):539-46 [17714470.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2007;8:215-39 [17506656.001]
  • [Cites] Nature. 2007 Oct 11;449(7163):682-8 [17898713.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16170-5 [17911264.001]
  • [Cites] Gastroenterol Clin North Am. 2007 Dec;36(4):831-49, vi [17996793.001]
  • [Cites] Cancer Biol Ther. 2007 Aug;6(8):1284-8 [17660710.001]
  • [Cites] J Biol Chem. 2008 Jan 11;283(2):1026-33 [17991735.001]
  • (PMID = 20332664.001).
  • [ISSN] 1424-3911
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA062924; United States / NCI NIH HHS / CA / P50CA062924
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / MIRN155 microRNA, human; 0 / MIRN21 microRNA, human; 0 / MIRN221 microRNA, human; 0 / MicroRNAs
  • [Other-IDs] NLM/ PMC2865485
  •  go-up   go-down


7. Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA: Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study. Cancer Invest; 2008 Feb;26(1):47-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study.
  • BACKGROUND: No therapeutic standard of care exists for patients with advanced pancreatic cancer who progress following first-line treatment with a gemcitabine-based regimen.
  • There is evidence of synergistic activity between docetaxel and irinotecan, and the combination of these two agents has shown promising efficacy in the first-line setting for advanced pancreatic cancer.
  • METHODS: Eligible patients with metastatic pancreatic adenocarcinoma were required to have an elevated serum CA19-9 (> 2x ULN) and exposure to one or two prior chemotherapy regimens, including one gemcitabine-based.
  • CONCLUSIONS: The combination of docetaxel and irinotecan given on a 21-day cycle is associated with excess toxicity in gemcitabine-refractory patients with advanced pancreatic cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / toxicity. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18181045.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; 7673326042 / irinotecan; B76N6SBZ8R / gemcitabine; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


8. Novarino A, Satolli MA, Chiappino I, Giacobino A, Bellone G, Rahimi F, Milanesi E, Bertetto O, Ciuffreda L: Oxaliplatin, 5-fluorouracil, and leucovorin as second-line treatment for advanced pancreatic cancer. Am J Clin Oncol; 2009 Feb;32(1):44-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oxaliplatin, 5-fluorouracil, and leucovorin as second-line treatment for advanced pancreatic cancer.
  • OBJECTIVE: A phase II study was performed to assess the activity of oxaliplatin plus 5-fluorouracil (5-FU) modulated by leucovorin, as second-line treatment in locally advanced or metastatic pancreas adenocarcinoma pretreated with gemcitabine-containing schedule.
  • RESULTS: Twenty-three patients affected with metastatic (16) or locally advanced (7) pancreas adenocarcinoma were involved in this study.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Pancreatic Neoplasms / drug therapy. Salvage Therapy

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19194124.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


9. Wang Y, Xie SL, Wang CF, Liu SM, Shan Y, Zhao DB, Liu Q, Luo W, Zhao P: [Clinical and pathological analysis of 114 cases with non-ductal pancreatic adenocarcinoma occupying lesions]. Zhonghua Yi Xue Za Zhi; 2010 Apr 27;90(16):1089-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical and pathological analysis of 114 cases with non-ductal pancreatic adenocarcinoma occupying lesions].
  • OBJECTIVE: To improve the diagnosis and treatment of non-ductal pancreatic adenocarcinoma-occupying lesions.
  • METHODS: A retrospective analysis was made for 114 cases of pancreatic non-ductal adenocarcinoma-occupying pathologically confirmed lesions. RESULTS:.
  • (4) pancreaticoduodenectomy was performed in 26 patients, distal pancreatectomy in 53, tumor enucleation in 15, segmental pancreatectomy in 9, partial resection in 3, duodenum-preserving pancreatic head resection in 1 and palliative surgery (either cholecystojejunostomy anastomosis or gastrojejunostomy) in 7;.
  • (5) pathologic analysis revealed 35 solid pseudopapillary neoplasm of pancreas, 28 pancreatic endocrine tumors, 18 focal chronic pancreatitis, 11 serous cystic neoplasms, 9 mucinous cystic neoplasms, 4 pancreatic cysts, 3 acinar cell carcinomas, 2 pancreatic cavernous hemangiomas, 1 sarcoma of pancreas, 1 sarcomatoid carcinoma of pancreas, 1 pancreatic schwannoma and 1 pancreatic neuroblastoma.
  • CONCLUSION: The non-ductal pancreatic adenocarcinoma-occupying lesions have no specific clinical presentation or serum tumor marker.
  • [MeSH-major] Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20646423.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen
  •  go-up   go-down


10. Guo JH, Wang WJ, Liao P, Zhang CY, Jin DY, Lou WH, Zhang SC: [Application of serum protein profiling in diagnosis, prognosis and evaluation of curative effect of pancreatic adenocarcinoma]. Zhonghua Zhong Liu Za Zhi; 2010 Jan;32(1):33-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Application of serum protein profiling in diagnosis, prognosis and evaluation of curative effect of pancreatic adenocarcinoma].
  • OBJECTIVE: To establish decision tree and logistic regression classification models for diagnosing pancreatic adenocarcinoma (PaCa) and for screening serum biomarkers related to evaluation of different stages and curative effects.
  • METHODS: Serum samples obtained from subjects with pancreatic adenocarcinoma (n = 58) and normal pancreas (n = 51) were applied to strong anion exchange chromatography (SAX2) chips for protein profiling by SELDI-TOF-MS to screen multiple serum biomarkers.
  • RESULTS: Average of 61 mass peaks were detected at the molecular range of 2000-30,000, ten decision trees with the highest cross validation rate were chosen to construct the classification models, which can differentiate PaCa from normal pancreas with a sensitivity of 83.3% and a specificity of 100%.
  • CONCLUSION: Decision tree and logistic regression classification models of the mass peaks screened by SELDI-TOF-MS serum profiling can be used to differentiate pancreatic adenocarcinoma from normal pancreas, and is superior to CA 199.
  • The detected mass peaks are helpful for the evaluation of curative effect and prognosis of pancreatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / blood. Biomarkers, Tumor / blood. Blood Proteins / analysis. Pancreatic Neoplasms / blood

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20211064.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Blood Proteins
  •  go-up   go-down


11. Gulluoglu MG, Karayigit E, Ozden I, Kapran Y, Dizdaroglu F: Does HepPar-1 immunoexpression have a role in differential diagnosis of periampullary cancer? Pathology; 2008 Jan;40(1):35-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does HepPar-1 immunoexpression have a role in differential diagnosis of periampullary cancer?
  • We assessed the immunoexpression rates of HepPar-1, CDX2 and MUC2 antibodies in different subtypes of periampullary adenocarcinomas (PAC), intestinal and pancreatobiliary, in order to assess their impact on differential diagnosis of this group of cancers.
  • The expression of antibodies was also measured in ductal adenocarcinoma of the pancreatic head (DAPH).
  • METHODS: Sixty-five patients with PAC and DAPH who underwent pancreatic Whipple resection constituted the study cohort.
  • In addition to CDX2 and MUC2 antibodies, HepPar-1 immunoexpression seems to have a potential role in differential diagnosis of PACs.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Antibodies, Monoclonal / metabolism. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Pancreatic Ductal / metabolism. Common Bile Duct Neoplasms / diagnosis. Common Bile Duct Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Antigens, Neoplasm / immunology. Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Common Bile Duct / metabolism. Common Bile Duct / pathology. Diagnosis, Differential. Female. Homeodomain Proteins / immunology. Homeodomain Proteins / metabolism. Humans. Male. Middle Aged. Mucin-2. Mucins / immunology. Mucins / metabolism. Pancreatic Ducts / metabolism. Pancreatic Ducts / pathology. Retrospective Studies. Sensitivity and Specificity

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18038313.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / MUC2 protein, human; 0 / Mucin-2; 0 / Mucins
  •  go-up   go-down


12. Paklina OV, Setdikova GR: [Immunohistochemical study of mucins in chronic pancreatitis and ductal adenocarcinoma of the pancreas]. Arkh Patol; 2008 Jul-Aug;70(4):13-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Immunohistochemical study of mucins in chronic pancreatitis and ductal adenocarcinoma of the pancreas].
  • Based on the results of an immunohistological study of MUC1, MUC2, MUC4, MUC5AC, and MUC6 in pancreatic tissue from 50 patients with chronic pancreatitis (CP) and 50 patients with ductal adenocarcinoma (DAC), the authors showed altered mucin immunological responsiveness in severe forms of CP, in the foci of PanIN and DAC.
  • They also revealed that determination of mucin expression may be used in the differential diagnosis of pancreatic cancer.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / metabolism. Mucins / metabolism. Neoplasm Proteins / metabolism. Pancreatic Neoplasms / metabolism. Pancreatitis, Chronic / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Retrospective Studies


13. Cheung MT, Lo IL: IgG4-related sclerosing lymphoplasmacytic pancreatitis and cholangitis mimicking carcinoma of pancreas and Klatskin tumour. ANZ J Surg; 2008 Apr;78(4):252-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IgG4-related sclerosing lymphoplasmacytic pancreatitis and cholangitis mimicking carcinoma of pancreas and Klatskin tumour.
  • The term 'autoimmune sclerosing pancreatocholangitis' was used as it was believed that they belonged to a range of disease involving both pancreas and biliary tree.
  • RESULTS: A total of five patients with clinical diagnosis of IgG4-related autoimmune pancreatitis or cholangitis were analysed.
  • CONCLUSION: With the growing awareness of this relatively recently characterized clinical entity and its similar presentation to pancreatic carcinoma or bile duct cholangiocarcinoma, it is important for autoimmune sclerosing pancreatocholangitis to be included in the differential diagnosis of pancreaticobiliary disease.
  • [MeSH-major] Adenocarcinoma / diagnosis. Cholangitis, Sclerosing / immunology. Immunoglobulin G / immunology. Klatskin Tumor / diagnosis. Pancreatic Neoplasms / diagnosis. Pancreatitis / immunology
  • [MeSH-minor] Aged. Autoimmune Diseases / diagnosis. Autoimmune Diseases / immunology. Autoimmune Diseases / surgery. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Plasma Cells / immunology. Retrospective Studies

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18366395.001).
  • [ISSN] 1445-2197
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Immunoglobulin G
  •  go-up   go-down


14. Wolkersdörfer GW, Thiede C, Fischer R, Ehninger G, Haag C: Adenoviral p53 gene transfer and gemcitabine in three patients with liver metastases due to advanced pancreatic carcinoma. HPB (Oxford); 2007;9(1):16-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoviral p53 gene transfer and gemcitabine in three patients with liver metastases due to advanced pancreatic carcinoma.
  • BACKGROUND: Current therapies for adenocarcinoma of the pancreas do not improve the life expectancy of patients.
  • METHODS: In a non-randomized pilot trail we tested whether a local therapy based upon an adenoviral gene transfer of wild type p53 in combination with gemcitabine administration would be safe in patients with liver metastases due to pancreatic carcinoma.
  • Further trials are warranted to improve treatment and life expectancy of patients suffering from fatal diseases such as pancreatic carcinoma.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Toxicol Sci. 2002 Feb;65(2):256-65 [11812930.001]
  • [Cites] Hum Gene Ther. 2002 Jan 1;13(1):125-8 [11779416.001]
  • [Cites] Cancer Gene Ther. 2002 Mar;9(3):254-9 [11896441.001]
  • [Cites] Cancer Gene Ther. 2002 Jul;9(7):553-66 [12082455.001]
  • [Cites] Cancer Gene Ther. 2002 Jul;9(7):567-72 [12082456.001]
  • [Cites] Hum Gene Ther. 2002 Jan 1;13(1):129-41 [11779417.001]
  • [Cites] Hum Gene Ther. 2002 Jan 1;13(1):143-54 [11779418.001]
  • [Cites] Ann Surg Oncol. 1998 Dec;5(8):681-8 [9869513.001]
  • [Cites] Chin Med J (Engl). 2002 May;115(5):726-31 [12133543.001]
  • [Cites] Mol Ther. 2002 Aug;6(2):287-97 [12349828.001]
  • [Cites] Int J Cancer. 2002 Nov 1;102(1):51-9 [12353234.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6070-9 [12414631.001]
  • [Cites] Cancer Gene Ther. 2002 Dec;9(12):979-86 [12522437.001]
  • [Cites] Cancer Gene Ther. 2002 Dec;9(12):1036-42 [12522442.001]
  • [Cites] Mol Ther. 2003 Jan;7(1):35-43 [12573616.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):555-61 [12576418.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):693-702 [12576437.001]
  • [Cites] Hum Cell. 2002 Sep;15(3):138-50 [12703544.001]
  • [Cites] Mol Genet Metab. 2003 Sep-Oct;80(1-2):148-58 [14567964.001]
  • [Cites] Br J Haematol. 2003 Dec;123(5):903-5 [14632782.001]
  • [Cites] Hum Gene Ther. 2003 Nov 20;14(17):1631-41 [14633405.001]
  • [Cites] J Clin Oncol. 2004 Feb 15;22(4):592-601 [14726502.001]
  • [Cites] J Am Coll Surg. 2004 May;198(5):722-31 [15110805.001]
  • [Cites] Br J Surg. 2004 May;91(5):586-94 [15122610.001]
  • [Cites] J Gene Med. 2004 Jun;6(6):652-62 [15170736.001]
  • [Cites] Int J Cancer. 1995 Nov 27;63(5):673-9 [7591284.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Dec 20;91(26):12368-72 [7809043.001]
  • [Cites] Hum Gene Ther. 1994 Sep;5(9):1079-88 [7833367.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):3025-33 [8187092.001]
  • [Cites] Ann Surg. 1996 Mar;223(3):273-9 [8604907.001]
  • [Cites] Ann Surg. 1997 May;225(5):609-18; discussion 618-20 [9193188.001]
  • [Cites] J Surg Res. 1997 Apr;69(1):226-31 [9202675.001]
  • [Cites] Pancreas. 1997 Jul;15(1):25-34 [9211489.001]
  • [Cites] Surgery. 1997 Aug;122(2):428-33; discussion 433-4 [9288150.001]
  • [Cites] Pancreas. 1998 Mar;16(2):107-13 [9510131.001]
  • [Cites] J Immunol. 1998 Jan 15;160(2):691-9 [9551904.001]
  • [Cites] Gene Ther. 1998 Apr;5(4):451-8 [9614568.001]
  • [Cites] Hum Pathol. 1999 Feb;30(2):123-9 [10029438.001]
  • [Cites] Hum Gene Ther. 1999 Apr 10;10(6):995-1008 [10223733.001]
  • [Cites] Cancer Gene Ther. 1999 Sep-Oct;6(5):428-36 [10505853.001]
  • [Cites] Blood. 1999 Dec 15;94(12):4084-92 [10590053.001]
  • [Cites] Clin Cancer Res. 2000 Mar;6(3):798-806 [10741699.001]
  • [Cites] Mol Biotechnol. 2000 Jan;14(1):59-72 [10911615.001]
  • [Cites] J Gene Med. 2000 Sep-Oct;2(5):361-7 [11045430.001]
  • [Cites] Mol Ther. 2001 Jan;3(1):28-35 [11162308.001]
  • [Cites] Hum Gene Ther. 2001 Feb 10;12(3):219-26 [11177559.001]
  • [Cites] Gene Ther. 2001 Feb;8(4):308-15 [11313805.001]
  • [Cites] Mol Ther. 2001 Apr;3(4):425-8 [11319902.001]
  • [Cites] Mol Ther. 2001 May;3(5 Pt 1):708-22 [11356076.001]
  • [Cites] Thromb Haemost. 2001 Jun;85(6):1079-85 [11434688.001]
  • [Cites] Surgery. 2001 Aug;130(2):280-8 [11490361.001]
  • [Cites] Mol Ther. 2001 Sep;4(3):182-91 [11545608.001]
  • [Cites] Hum Gene Ther. 2002 Jan 1;13(1):113-24 [11779415.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1562-9 [11896105.001]
  • (PMID = 18333108.001).
  • [ISSN] 1365-182X
  • [Journal-full-title] HPB : the official journal of the International Hepato Pancreato Biliary Association
  • [ISO-abbreviation] HPB (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2020772
  •  go-up   go-down


15. Baumgaertner I, Corcos O, Couvelard A, Sauvanet A, Rebours V, Vullierme MP, Hentic O, Hammel P, Lévy P, Ruszniewski P: Prevalence of extrapancreatic cancers in patients with histologically proven intraductal papillary mucinous neoplasms of the pancreas: a case-control study. Am J Gastroenterol; 2008 Nov;103(11):2878-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of extrapancreatic cancers in patients with histologically proven intraductal papillary mucinous neoplasms of the pancreas: a case-control study.
  • BACKGROUND: Some studies have suggested that intraductal papillary mucinous neoplasms (IPMN) of the pancreas could be associated with extrapancreatic cancers (EPC)--especially from gastric and colorectal origin.
  • Most of the EPCs precede the diagnosis of IPMN.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / pathology. Neoplasms, Multiple Primary / diagnosis. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18853975.001).
  • [ISSN] 1572-0241
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Kaifi JT, Cataldegirmen G, Wachowiak R, Schurr PG, Kleinhans H, Kosti G, Yekebas EF, Mann O, Kutup A, Kalinin V, Strate T, Izbicki JR: Short tandem repeat polymorphisms of exon 4 in Kazal-type gene ECRG2 in pancreatic carcinoma and chronic pancreatitis. Anticancer Res; 2007 Jan-Feb;27(1A):69-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Short tandem repeat polymorphisms of exon 4 in Kazal-type gene ECRG2 in pancreatic carcinoma and chronic pancreatitis.
  • Kazal-type genes are associated with cancer and pancreatic disease.
  • The aim of the present study was to examine whether ECRG2 STR polymorphisms are associated with pancreatic carcinoma and chronic pancreatitis.
  • MATERIALS AND METHODS: A total of 209 surgically treated patients were analyzed, 92 with pancreatic adenocarcinoma and 117 with chronic pancreatitis.
  • RESULTS: ECRG2 STR of highest incidence was TCA3/TCA3 [47 (51%) in pancreatic carcinoma; 59 (50%) in pancreatitis patients], followed by the TCA3/TCA4 [37 (40%); 54 (46%)] and TCA4/TCA4 [8 (9%); 4 (4%)] genotypes.
  • No correlation in frequency of STRs comparing chronic pancreatitis and pancreatic cancer was determined using the Chi-squared test (p = 0.23).
  • CONCLUSION: The data show that ECRG2 STR polymorphism TCA3/TCA3 in exon 4 is the most prevalent polymorphism found in pancreatic adenocarcinoma and chronic pancreatitis detected in peripheral blood.
  • None of the polymorphisms was associated with poor clinical outcome in pancreatic cancer patients.
  • [MeSH-major] Adenocarcinoma / genetics. Microsatellite Repeats. Pancreatic Neoplasms / genetics. Pancreatitis, Chronic / genetics. Tumor Suppressor Proteins / genetics

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17352218.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Proteinase Inhibitory Proteins, Secretory; 0 / SPINK7 protein, human; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


17. Sceusi EL, Wray CJ: Pancreatic adenocarcinoma in a patient with situs inversus: a case report of this rare coincidence. World J Surg Oncol; 2009;7:98
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic adenocarcinoma in a patient with situs inversus: a case report of this rare coincidence.
  • BACKGROUND: Situs inversus (SI) is a relatively rare occurrence in patients with pancreatic adenocarcinoma.
  • Pancreatic resection in these patients has rarely been described.
  • CT scan imaging is a principle modality for detecting pancreatic cancer and its use in SI patients is seldom reported.
  • CASE PRESENTATION: We report a 48 year old woman with SI who, despite normal CT scan 8 months earlier, presented with obstructive jaundice and a pancreatic head mass requiring a pancreaticoduodenectomy.
  • The surgical pathology report demonstrated pancreatic adenocarcinoma.
  • CONCLUSION: SI is a rare condition with concurrent pancreatic cancer being even rarer.
  • Additionally, radiographic imaging has significantly improved detection of early pancreatic cancer; however, there continues to be a need for improved detection of small neoplasms.
  • [MeSH-major] Adenocarcinoma / complications. Pancreatic Neoplasms / complications. Situs Inversus / complications

  • Genetic Alliance. consumer health - Situs inversus.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Radiol. 2009 Oct;19(10):2448-55 [19415290.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Dec;6(12):1301-8 [18948228.001]
  • [Cites] Transplant Proc. 2008 Jun;40(5):1792-5 [18589199.001]
  • [Cites] Eur J Surg Oncol. 2007 May;33(4):524-7 [17081721.001]
  • [Cites] Wiad Lek. 2006;59(9-10):707-9 [17338134.001]
  • [Cites] Curr Opin Gastroenterol. 2006 Sep;22(5):512-9 [16891882.001]
  • [Cites] AJR Am J Roentgenol. 1998 May;170(5):1315-22 [9574609.001]
  • [Cites] Semin Cell Dev Biol. 1998 Feb;9(1):89-99 [9572118.001]
  • [Cites] J Clin Gastroenterol. 1997 Mar;24(2):92-6 [9077725.001]
  • [Cites] AJR Am J Roentgenol. 2004 Apr;182(4):897-903 [15039161.001]
  • [Cites] AJR Am J Roentgenol. 2004 Mar;182(3):619-23 [14975959.001]
  • [Cites] Am J Surg. 2003 Jun;185(6):606-7 [12781900.001]
  • [Cites] Radiol Clin North Am. 2002 Dec;40(6):1263-72 [12479710.001]
  • [Cites] Radiology. 2002 Sep;224(3):764-8 [12202711.001]
  • [Cites] Am J Med Genet. 2001 Jul 15;101(4):345-55 [11471158.001]
  • [Cites] Surg Radiol Anat. 2000;22(5-6):293-7 [11236325.001]
  • [Cites] Radiographics. 2002 Nov-Dec;22(6):1439-56 [12432114.001]
  • (PMID = 20021643.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2803176
  •  go-up   go-down


18. Talar-Wojnarowska R, Gasiorowska A, Smolarz B, Romanowicz-Makowska H, Kulig A, Malecka-Panas E: Tumor necrosis factor alpha and interferon gamma genes polymorphisms and serum levels in pancreatic adenocarcinoma. Neoplasma; 2009;56(1):56-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor necrosis factor alpha and interferon gamma genes polymorphisms and serum levels in pancreatic adenocarcinoma.
  • The aim of our study was to assess the clinical significance of -308G/A TNF-alpha and +874A/T INF-gamma genes polymorphisms as well as TNF-alpha and INF-gamma serum levels in pancreatic adenocarcinoma (PA) and chronic pancreatitis (CP) as regards to healthy volunteers.
  • We studied 41 patients with pancreatic adenocarcinoma, 56 with chronic pancreatitis and 50 healthy volunteers.
  • -308G/A TNF-alpha and +874A/T INF-gamma genes polymorphisms probably do not play important role in pancreatic diseases.
  • Key words: pancreatic adenocarcinoma, tumor necrosis factor alpha, interferon gamma, cytokines, polymorphism.
  • [MeSH-major] Adenocarcinoma / genetics. Interferon-gamma / genetics. Pancreatic Neoplasms / genetics. Tumor Necrosis Factor-alpha / genetics

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19152246.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


19. Dimou AT, Syrigos KN, Saif MW: Novel agents for the treatment of pancreatic adenocarcinoma: any light at the end of the tunnel? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010. JOP; 2010;11(4):324-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel agents for the treatment of pancreatic adenocarcinoma: any light at the end of the tunnel? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010.
  • Pancreatic cancer is a disease with dismal prognosis and treatment options are limited.
  • A number of pancreatic cancer clinical trials that included a novel agent among their arms were presented at the recent 2010 American Society of Clinical Oncology (ASCO) Annual Meeting.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Medical Oncology / methods. Medical Oncology / trends. Pancreatic Neoplasms / drug therapy


20. Mané JM, Sancho A, Muñoz A, Rubio I, Fernández R, Carrera S, Fuente N, Ballesteros D, Casas R, Marrodán I, Mielgo X, López-Vivanco G: Fixed-dose-rate gemcitabine infusion in patients with advanced pancreatic or biliary tree adenocarcinoma. Tumori; 2010 May-Jun;96(3):405-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fixed-dose-rate gemcitabine infusion in patients with advanced pancreatic or biliary tree adenocarcinoma.
  • AIMS AND BACKGROUND: Gemcitabine is an effective agent in pancreatic adenocarcinoma.
  • We conducted a trial to confirm efficacy and toxicity of fixed-dose-rate gemcitabine in patients with pancreatic or biliary tree adenocarcinoma.
  • METHODS: Eligible patients with locally advanced or metastatic pancreatic or biliary tree adenocarcinoma received fixed-dose-rate gemcitabine at a dose of 1500 mg/m(2) at a rate of 10 mg/m(2)/min weekly for 3 weeks every 28 days.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / administration & dosage. Biliary Tract Neoplasms / drug therapy. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20845800.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


21. Matsubayashi H, Infante JR, Winter J, Klein AP, Schulick R, Hruban R, Visvanathan K, Goggins M: Tumor COX-2 expression and prognosis of patients with resectable pancreatic cancer. Cancer Biol Ther; 2007 Oct;6(10):1569-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor COX-2 expression and prognosis of patients with resectable pancreatic cancer.
  • BACKGROUND: COX-2 is overexpressed in many cancers and precursor neoplasms including pancreatic cancer and in experimental settings its overexpression has multiple tumorigenic effects including increasing proliferation and angiogenesis, and inhibition of apoptotic and immunologic responses.
  • We evaluated the prognostic significance of COX-2 expression in pancreatic adenocarcinomas.
  • PATIENTS AND METHODS: We analyzed COX-2 expression by immunohistochemistry in a prospective cohort of 299 patients with resectable infiltrating adenocarcinoma of the pancreas that had undergone a pancreaticoduodenectomy at Johns Hopkins Hospital between January of 1998 and July of 2003.
  • The survival associated with COX-2 expression was assessed by Kaplan-Meier survival analysis and multivariate Cox proportional hazards regression models that controlled for other known prognostic factors associated with pancreas cancer mortality.
  • RESULTS: By Kaplan-Meier analysis, patients whose pancreatic cancer cells expressed COX-2 (median survival, 15 months) had a significantly worse prognosis than patients whose tumor cells did not express COX-2 (median survival, 20 months; log rank, p = 0.002).
  • CONCLUSIONS: Tumor COX-2 expression portends a poor prognosis for patients with resected adenocarcinoma of the pancreas, particularly in tumors > or =3 cm.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / surgery. Biomarkers, Tumor / analysis. Cyclooxygenase 2 / analysis. Pancreatic Neoplasms / mortality. Pancreatic Neoplasms / surgery

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Pancreatic cancer 2.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18000398.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA62924; United States / NCI NIH HHS / CA / CA90709
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


22. Raina A, Krasinskas AM, Greer JB, Lamb J, Fink E, Moser AJ, Zeh HJ 3rd, Slivka A, Whitcomb DC: Serum immunoglobulin G fraction 4 levels in pancreatic cancer: elevations not associated with autoimmune pancreatitis. Arch Pathol Lab Med; 2008 Jan;132(1):48-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum immunoglobulin G fraction 4 levels in pancreatic cancer: elevations not associated with autoimmune pancreatitis.
  • CONTEXT: Autoimmune pancreatitis is an uncommon, inflammatory disease of the pancreas that presents with clinical features, such as painless jaundice and a pancreatic mass, similar to those caused by pancreatic cancer.
  • Patients with autoimmune pancreatitis frequently have elevated serum immunoglobulin G fraction 4 (IgG4) levels, and their pancreatic tissue may show IgG4-positive plasma cell infiltration.
  • It is imperative to differentiate autoimmune pancreatitis from pancreatic cancer because autoimmune pancreatitis typically responds to corticosteroid treatment.
  • OBJECTIVE: To prospectively measure serum IgG4 levels in pancreatic cancer patients to ascertain whether increased levels might be present in this North American population.
  • DESIGN: We collected blood samples and phenotypic information on 71 consecutive pancreatic cancer patients and 103 healthy controls who visited our clinics between October 2004 and April 2006.
  • CONCLUSIONS: As many as 7% of patients with pancreatic cancer have serum IgG4 levels above 135 mg/dL.
  • In patients with pancreatic mass lesions and suspicion of cancer, an IgG4 level measuring between 135 and 200 mg/dL should be interpreted cautiously and not accepted as diagnostic of autoimmune pancreatitis without further evaluation.
  • [MeSH-major] Adenocarcinoma / immunology. Autoimmune Diseases / immunology. Immunoglobulin G / blood. Pancreatic Neoplasms / immunology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / immunology. Diagnosis, Differential. Female. Humans. Immunodiffusion. Male. Middle Aged. Prospective Studies. Reference Values


23. Ito K, Fujita N, Noda Y, Kobayashi G, Kimura K, Horaguchi J, Takasawa O, Kobari M: Intraductal tubular adenocarcinoma of the pancreas diagnosed before surgery by transpapillary biopsy: case report and review. Gastrointest Endosc; 2005 Feb;61(2):325-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal tubular adenocarcinoma of the pancreas diagnosed before surgery by transpapillary biopsy: case report and review.
  • [MeSH-major] Adenocarcinoma / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for tubular adenocarcinoma .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15729258.001).
  • [ISSN] 0016-5107
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 25
  •  go-up   go-down


24. Sato N, Parker AR, Fukushima N, Miyagi Y, Iacobuzio-Donahue CA, Eshleman JR, Goggins M: Epigenetic inactivation of TFPI-2 as a common mechanism associated with growth and invasion of pancreatic ductal adenocarcinoma. Oncogene; 2005 Jan 27;24(5):850-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic inactivation of TFPI-2 as a common mechanism associated with growth and invasion of pancreatic ductal adenocarcinoma.
  • Using microarrays, we have screened for genes reactivated by drugs that modify epigenetic mechanisms in pancreatic cancer cells.
  • We therefore investigated the expression and methylation patterns of the TFPI-2 gene in pancreatic adenocarcinoma, and determined its role in tumor growth and invasion.
  • In contrast to its abundant expression in normal pancreas, TFPI-2 mRNA was undetectable in a high fraction of pancreatic cancer cell lines and in primary pancreatic ductal neoplasms (IPMNs).
  • Aberrant methylation of TFPI-2 was also detected in 73% (102/140) of pancreatic cancer xenografts and primary pancreatic adenocarcinomas, was more likely in older patients with pancreatic cancer, and significantly correlated with progression of IPMNs (P=0.0002).
  • Restored expression of the TFPI-2 gene in nonexpressing pancreatic cancer cells resulted in marked suppression in their proliferation, migration, and invasive potential in vitro.
  • We thus conclude that epigenetic inactivation of TFPI-2 is a common mechanism that contributes to the aggressive phenotype of pancreatic ductal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Azacitidine / analogs & derivatives. Azacitidine / toxicity. Carcinoma, Pancreatic Ductal / genetics. Glycoproteins / genetics. Pancreatic Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15592528.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA62924; United States / NCI NIH HHS / CA / CA90709
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / DNA Primers; 0 / Glycoproteins; 0 / Hydroxamic Acids; 0 / tissue-factor-pathway inhibitor 2; 3X2S926L3Z / trichostatin A; 776B62CQ27 / decitabine; M801H13NRU / Azacitidine
  •  go-up   go-down


25. Rubenstein JH, Scheiman JM, Anderson MA: A clinical and economic evaluation of endoscopic ultrasound for patients at risk for familial pancreatic adenocarcinoma. Pancreatology; 2007;7(5-6):514-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A clinical and economic evaluation of endoscopic ultrasound for patients at risk for familial pancreatic adenocarcinoma.
  • BACKGROUND AND AIMS: Approximately 10% of pancreatic adenocarcinoma is familial.
  • PTP provided the longest life expectancy if the lifetime risk of pancreatic cancer was at least 46%, and provided the most QALYs if the risk was at least 68%.
  • CONCLUSIONS: FDRs from familial pancreatic cancer kindreds, who have EUS findings of chronic pancreatitis, have increased risk for cancer, but their precise risk is unknown.
  • [MeSH-major] Adenocarcinoma / ultrasonography. Endosonography / economics. Pancreatic Neoplasms / ultrasonography. Pancreatitis, Chronic / complications
  • [MeSH-minor] Biopsy, Fine-Needle / economics. Decision Support Techniques. Genetic Predisposition to Disease. Health Care Costs. Humans. Male. Markov Chains. Middle Aged. Pancreas / ultrasonography. Pancreatectomy / economics. Quality of Life. Risk

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 S. Karger AG, Basel and IAP.
  • (PMID = 17912015.001).
  • [ISSN] 1424-3911
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


26. Abiatari I, Kiladze M, Kerkadze V, Friess H, Kleeff J: Expression of YPEL1 in pancreatic cancer cell lines and tissues. Georgian Med News; 2009 Oct;(175):60-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of YPEL1 in pancreatic cancer cell lines and tissues.
  • Recently we have identified YPEL1 as a gene whose expression is deregulation in perineural invasive pancreatic cancer cells.
  • In this study we assessed the expression of YPEL1 in normal and diseased pancreatic tissues and pancreatic cancer cell lines.
  • Quantitative real time polymerase chain reaction was used to analyze the expression of YPEL1 mRNA in nine cultured pancreatic cancer cell lines and pancreatic bulk tissues of the normal pancreas (n=19), chronic pancreatitis (n=19) and pancreatic adenocarcinoma tissues (n=31).
  • Quantitative real time polymerase chain reaction analysis revealed a significant down-regulation of YPEL1 mRNA expression in pancreatic adenocarcinoma tissues compared to normal tissues (54.1+/-5.2 vs. 85.8+/-14.1 copies/10,000 copies cpb) and low expression of this gene indicated a tendency for better survival of pancreatic cancer patients (16 vs. 13 months; p=0.17).
  • Expression of YPEL1 mRNA was present in all tested pancreatic cancer cell lines with comparably low to moderate expression levels of 4.3 - 88.0 copies/10,000 copies cpb.
  • Reduced expression of YPEL1 in pancreatic cancer might be related to perineural invasion. and prognosis.
  • Further studies are required to better assess the role of human YPEL1 in pancreatic cancer pathogenesis.
  • [MeSH-major] Gene Expression / genetics. Pancreatic Neoplasms / genetics. Pancreatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19893129.001).
  • [ISSN] 1512-0112
  • [Journal-full-title] Georgian medical news
  • [ISO-abbreviation] Georgian Med News
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Georgia (Republic)
  •  go-up   go-down


27. Freitas D, Fernandes Gdos S, Hoff PM, Cunha JE: Medical management of pancreatic adenocarcinoma. Pancreatology; 2009;9(3):223-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medical management of pancreatic adenocarcinoma.
  • Pancreatic cancer is the fourth leading cause of cancer death in the United States.
  • In 2008, an estimated 34,290 people died from pancreatic cancer and 37,680 new cases were diagnosed.
  • Despite modern treatment, 90% of patients die within 1 year of diagnosis.
  • In the present paper the English-language literature addressing the medical management in pancreatic cancer was reviewed.
  • Based on these data we will discuss the role of currently used chemotherapy and target therapy in pancreatic cancer, as well as perspectives of the emerging strategies that are arising in order to improve the outcomes of this complex disease.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Pancreatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 S. Karger AG, Basel.
  • (PMID = 19420981.001).
  • [ISSN] 1424-3911
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  • [Number-of-references] 112
  •  go-up   go-down


28. Moo-Young TA, Larson JW, Belt BA, Tan MC, Hawkins WG, Eberlein TJ, Goedegebuure PS, Linehan DC: Tumor-derived TGF-beta mediates conversion of CD4+Foxp3+ regulatory T cells in a murine model of pancreas cancer. J Immunother; 2009 Jan;32(1):12-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-derived TGF-beta mediates conversion of CD4+Foxp3+ regulatory T cells in a murine model of pancreas cancer.
  • We reported previously that Treg are significantly elevated in the peripheral blood of patients with pancreas cancer and that in a murine pancreas cancer model induction of Treg seems to be transforming growth factor (TGF)-beta dependent.
  • The murine pancreas cancer cell line Pan02 produces high levels of TGF-beta both in vitro and in vivo.
  • Collectively, these observations further support the role of TGF-beta in the induction of Treg in pancreas adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 15;102(11):4091-6 [15753306.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):2078-93 [15774796.001]
  • [Cites] Immunol Res. 2005;32(1-3):155-68 [16106066.001]
  • [Cites] Autoimmun Rev. 2005 Nov;4(8):579-86 [16214099.001]
  • [Cites] Cancer Biol Ther. 2005 Mar;4(3):342-6 [15846066.001]
  • [Cites] Curr Pharm Des. 2005;11(27):3501-9 [16248804.001]
  • [Cites] J Clin Invest. 2005 Dec;115(12):3623-33 [16308572.001]
  • [Cites] Nat Immunol. 2005 Dec;6(12):1219-27 [16244650.001]
  • [Cites] J Immunol. 2006 Jan 15;176(2):984-90 [16393984.001]
  • [Cites] Cancer Immunol Immunother. 2006 Jul;55(7):775-84 [16167144.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Apr 4;103(14):5460-5 [16567639.001]
  • [Cites] Gut. 2006 May;55(5):671-80 [16162681.001]
  • [Cites] Nat Med. 2004 Sep;10(9):942-9 [15322536.001]
  • [Cites] J Immunol. 2006 Jul 15;177(2):896-904 [16818744.001]
  • [Cites] Cancer Causes Control. 2006 Oct;17(8):1077-82 [16933058.001]
  • [Cites] J Immunol. 2007 Feb 15;178(4):2155-62 [17277120.001]
  • [Cites] J Immunol. 2007 Mar 1;178(5):2883-92 [17312132.001]
  • [Cites] Int J Cancer. 2007 Jun 15;120(12):2723-33 [17315189.001]
  • [Cites] Cancer Immunol Immunother. 2007 Sep;56(9):1429-42 [17265021.001]
  • [Cites] J Immunol. 2007 Oct 1;179(7):4919-28 [17878392.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):148-60 [18091047.001]
  • [Cites] J Immunother. 2008 Feb-Mar;31(2):189-98 [18481388.001]
  • [Cites] J Immunol. 1999 Nov 15;163(10):5211-8 [10553041.001]
  • [Cites] Immunity. 2000 Feb;12(2):171-81 [10714683.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3 Suppl):925s-932s [11300493.001]
  • [Cites] Surg Clin North Am. 2001 Jun;81(3):715-39 [11459285.001]
  • [Cites] Nat Med. 2001 Oct;7(10):1118-22 [11590434.001]
  • [Cites] J Immunol. 2002 Sep 1;169(5):2756-61 [12193750.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):606-12 [12576425.001]
  • [Cites] Nat Immunol. 2003 Apr;4(4):330-6 [12612578.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4404-8 [14555512.001]
  • [Cites] J Exp Med. 2003 Dec 15;198(12):1875-86 [14676299.001]
  • [Cites] Annu Rev Immunol. 2004;22:531-62 [15032588.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4572-7 [15070759.001]
  • [Cites] J Immunol. 2004 Jun 15;172(12):7335-40 [15187109.001]
  • [Cites] Clin Immunol. 2005 Jan;114(1):52-60 [15596409.001]
  • [Cites] Contrib Nephrol. 2005;146:121-31 [15567926.001]
  • [Cites] Am J Pathol. 1999 Aug;155(2):537-47 [10433946.001]
  • [Cites] Cancer Res. 1999 Jul 1;59(13):3128-33 [10397255.001]
  • [Cites] J Immunol. 1995 Aug 1;155(3):1151-64 [7636184.001]
  • [Cites] J Immunother. 2006 Jul-Aug;29(4):416-24 [16799337.001]
  • (PMID = 19307989.001).
  • [ISSN] 1537-4513
  • [Journal-full-title] Journal of immunotherapy (Hagerstown, Md. : 1997)
  • [ISO-abbreviation] J. Immunother.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / T32 CA09621-11; United States / NCI NIH HHS / CA / T32 CA009621; United States / NCI NIH HHS / CA / K08 CA087018; United States / NCI NIH HHS / CA / K08 CA87018-01; United States / NIDDK NIH HHS / DK / P30 DK52574; United States / NIDDK NIH HHS / DK / P30 DK052574
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD4; 0 / Forkhead Transcription Factors; 0 / Foxp3 protein, mouse; 0 / Homeodomain Proteins; 0 / Receptors, Transforming Growth Factor beta; 0 / Transforming Growth Factor beta; 128559-51-3 / RAG-1 protein
  • [Other-IDs] NLM/ NIHMS236220; NLM/ PMC3862184
  •  go-up   go-down


29. Donadelli M, Dalla Pozza E, Costanzo C, Scupoli MT, Scarpa A, Palmieri M: Zinc depletion efficiently inhibits pancreatic cancer cell growth by increasing the ratio of antiproliferative/proliferative genes. J Cell Biochem; 2008 May 1;104(1):202-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Zinc depletion efficiently inhibits pancreatic cancer cell growth by increasing the ratio of antiproliferative/proliferative genes.
  • We investigated the ability of the zinc chelator N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine (TPEN) to reduce pancreatic cancer cell viability.
  • TPEN was much more efficient to inhibit pancreatic adenocarcinoma cell growth than a panel of anti-cancer drugs, including 5-fluorouracil, irinotecan, cisplatin, edelfosine, trichostatin A, mitomycin C, and gemcitabine, the gold standard chemotherapeutic agent for pancreatic cancer.
  • Moreover, TPEN showed a dose- and time-dependent anti-proliferative effect significantly higher on pancreatic cancer cells than on normal primary fibroblasts.
  • This effect may be explained by a significantly higher zinc depletion by TPEN in pancreatic cancer cells as compared to fibroblasts.
  • In this study, we suggest that zinc depletion may be an efficient strategy in the treatment of pancreatic cancer because of its reduced antiproliferative effect on normal cells.
  • [MeSH-major] Cell Proliferation / drug effects. Ethylenediamines / pharmacology. Gene Expression Regulation, Neoplastic. Pancreatic Neoplasms / therapy. Zinc / deficiency

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. ZINC, ELEMENTAL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17979179.001).
  • [ISSN] 1097-4644
  • [Journal-full-title] Journal of cellular biochemistry
  • [ISO-abbreviation] J. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chelating Agents; 0 / Ethylenediamines; 16858-02-9 / N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine; J41CSQ7QDS / Zinc
  •  go-up   go-down


30. Arikawa S, Uchida M, Shinagawa M, Uozumi J, Hayabuchi N, Okabe Y, Suga H, Yanagi K, Kinoshita H, Naitou Y: [The role of multi-detector-row computed tomograph in the diagnosis of intraductal papillary-mucinous tumors of the pancreas in comparison to endoscopic retrograde pancreatography, endoscopic ultrasonography, magnetic resonance cholangiopancreatography]. Nihon Shokakibyo Gakkai Zasshi; 2007 Mar;104(3):373-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The role of multi-detector-row computed tomograph in the diagnosis of intraductal papillary-mucinous tumors of the pancreas in comparison to endoscopic retrograde pancreatography, endoscopic ultrasonography, magnetic resonance cholangiopancreatography].
  • Thirty patients with intraductal papillary-mucinous tumor (IPMT) of the pancreas underwent multidetector-row CT (MD-CT) in addition to endoscopic retrograde pancreatography (ERP), and, in 27 cases magnetic resonance cholangiopancreatography (MRCP) and endoscopic ultrasonography (EUS).
  • The usefulness of MD-CT was investigated by comparing various imaging methods of the communication from the main pancreatic duct (MPD) to patulous/bulging papilla in addition to the indices for benign or malignant disease, the degree of dilation of the MPD, localization and size of cystic lesions, and presence or absence of neoplastic lesions, such as thickened walls and septa, intramural nodule, solid mass.
  • With MD-CT, dilation of the MPD and localization and size of cystic lesions were accurately assessed, even in patients with obstruction of the main pancreatic duct in whom ERP was difficult to perform regardless of the presence or absence of massive amount of mucus.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Diagnostic Imaging / methods. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17337874.001).
  • [ISSN] 0446-6586
  • [Journal-full-title] Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
  • [ISO-abbreviation] Nihon Shokakibyo Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


31. Zeng G, Germinaro M, Micsenyi A, Monga NK, Bell A, Sood A, Malhotra V, Sood N, Midda V, Monga DK, Kokkinakis DM, Monga SP: Aberrant Wnt/beta-catenin signaling in pancreatic adenocarcinoma. Neoplasia; 2006 Apr;8(4):279-89
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant Wnt/beta-catenin signaling in pancreatic adenocarcinoma.
  • The aim of this study is to examine the Wnt/beta-catenin pathway in patients with advanced pancreatic adenocarcinoma (n = 31).
  • Thus, Wnt/beta-catenin activation was observed in 65% of pancreatic adenocarcinomas, independently of beta-catenin gene mutations in most tumors.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Digestion. 1999 Nov-Dec;60(6):544-8 [10545724.001]
  • [Cites] Gastroenterology. 2005 Jul;129(1):285-302 [16012954.001]
  • [Cites] Bioessays. 1999 Dec;21(12):1021-30 [10580987.001]
  • [Cites] Oncogene. 1999 Nov 18;18(48):6776-84 [10597286.001]
  • [Cites] Science. 2000 Mar 3;287(5458):1606-9 [10733430.001]
  • [Cites] J Med Invest. 2000 Feb;47(1-2):47-55 [10740979.001]
  • [Cites] Development. 2001 Mar;128(6):871-81 [11222142.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3245-9 [11309273.001]
  • [Cites] Hepatology. 2001 May;33(5):1098-109 [11343237.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2001 Jan;6(1):37-52 [11467451.001]
  • [Cites] Mol Cell Biol. 2001 Sep;21(17):5857-68 [11486025.001]
  • [Cites] Development. 2005 Nov;132(21):4663-74 [16192304.001]
  • [Cites] Curr Opin Cell Biol. 2005 Oct;17(5):459-65 [16099633.001]
  • [Cites] Cancer Lett. 2006 Feb 28;233(2):328-37 [15893416.001]
  • [Cites] J Neurochem. 2001 Sep;78(6):1219-32 [11579131.001]
  • [Cites] Am J Pathol. 2001 Nov;159(5):1619-27 [11696422.001]
  • [Cites] Anticancer Res. 2001 Nov-Dec;21(6A):4127-34 [11911306.001]
  • [Cites] Cancer Res. 2002 Apr 1;62(7):2064-71 [11929826.001]
  • [Cites] Science. 2002 May 31;296(5573):1644-6 [12040179.001]
  • [Cites] Anticancer Res. 2002 Jul-Aug;22(4):2015-27 [12174879.001]
  • [Cites] J Cancer Res Clin Oncol. 2002 Oct;128(10):525-32 [12384795.001]
  • [Cites] Dev Dyn. 2002 Nov;225(3):260-70 [12412008.001]
  • [Cites] Oncogene. 2002 Nov 28;21(54):8293-301 [12447692.001]
  • [Cites] J Gastrointest Surg. 2002 Nov-Dec;6(6):838-43; discussion 844 [12504222.001]
  • [Cites] Gastroenterology. 2003 Jan;124(1):202-16 [12512043.001]
  • [Cites] J Pathol. 2003 Feb;199(2):185-90 [12533831.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2003;43:199-231 [12195027.001]
  • [Cites] Cancer Res. 2003 Feb 1;63(3):586-92 [12566300.001]
  • [Cites] Cancer Biol Ther. 2002 Nov-Dec;1(6):621-5 [12642683.001]
  • [Cites] Semin Oncol. 2003 Feb;30(1 Suppl 1):3-11 [12644979.001]
  • [Cites] Hepatology. 2003 Apr;37(4):824-32 [12668975.001]
  • [Cites] Ann Surg Oncol. 2003 Apr;10(3):284-90 [12679314.001]
  • [Cites] Cancer Lett. 2003 Apr 25;193(2):161-70 [12706873.001]
  • [Cites] J Clin Invest. 2003 May;111(9):1287-95 [12727920.001]
  • [Cites] J Cancer Res Clin Oncol. 2003 Apr;129(4):199-221 [12707770.001]
  • [Cites] Biochim Biophys Acta. 2003 Jun 5;1653(1):1-24 [12781368.001]
  • [Cites] Trends Cell Biol. 2003 Jun;13(6):328-35 [12791299.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Jul 18;307(1):188-97 [12849999.001]
  • [Cites] World J Surg. 2003 Oct;27(10):1075-84 [12925907.001]
  • [Cites] Gene Expr. 2003;11(3-4):141-7 [14686787.001]
  • [Cites] Gastroenterology. 2004 Apr;126(4):1134-46 [15057752.001]
  • [Cites] J Cell Biol. 1993 Feb;120(3):757-66 [8425900.001]
  • [Cites] Trends Genet. 1993 Sep;9(9):317-21 [8236461.001]
  • [Cites] Oncogene. 1995 Jan 5;10(1):177-84 [7824270.001]
  • [Cites] Development. 1995 Nov;121(11):3529-37 [8582267.001]
  • [Cites] EMBO J. 1997 Jul 1;16(13):3797-804 [9233789.001]
  • [Cites] Genes Dev. 1997 Dec 15;11(24):3286-305 [9407023.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Jun 29;247(3):851-8 [9647782.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8847-51 [9671767.001]
  • [Cites] Science. 1998 Sep 4;281(5382):1509-12 [9727977.001]
  • [Cites] Am J Pathol. 1999 Feb;154(2):325-9 [10027390.001]
  • [Cites] Nature. 1999 Apr 1;398(6726):431-6 [10201374.001]
  • [Cites] Int J Cancer. 1999 Aug 12;82(4):504-11 [10404062.001]
  • [Cites] Semin Liver Dis. 1999;19(3):235-42 [10518303.001]
  • [Cites] Oncol Rep. 1999 Nov-Dec;6(6):1253-6 [10523691.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] J Hepatol. 2005 Jul;43(1):132-41 [15893845.001]
  • [Cites] Adv Cancer Res. 2000;77:1-24 [10549354.001]
  • (PMID = 16756720.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK062277; United States / NIDDK NIH HHS / DK / 1R01DK62277
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Wnt Proteins; 0 / beta Catenin
  • [Other-IDs] NLM/ PMC1600679
  •  go-up   go-down


32. Pan JJ, Oh SH, Lee WC, Petersen BE: Bone marrow-derived progenitor cells could modulate pancreatic cancer tumorigenesis via peritumoral microenvironment in a rat model. Oncol Res; 2009;17(8):339-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone marrow-derived progenitor cells could modulate pancreatic cancer tumorigenesis via peritumoral microenvironment in a rat model.
  • Metaplastic tubular complexes (MTC) have been proposed as precursor lesions for pancreatic adenocarcinoma (PDAC).
  • After confirming engraftment, recipient animals received dimethylbenzanthracene (DMBA) implantation in their pancreas.
  • BMPC could modulate pancreatic cancer growth through tumor microenvironment.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Exp Pathol. 1999 Aug;80(4):205-15 [10583630.001]
  • [Cites] Cancer Gene Ther. 2008 Apr;15(4):231-40 [18202717.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4923-32 [11406572.001]
  • [Cites] Surgery. 2002 Feb;131(2):129-34 [11854689.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Mar;3(3):187-94 [11994739.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Lab Invest. 2003 Jun;83(6):853-9 [12808120.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Sep 12;309(1):232-40 [12943687.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5821-8 [14522905.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 20;101(3):781-6 [14711994.001]
  • [Cites] Am J Surg. 1982 Aug;144(2):243-9 [7102934.001]
  • [Cites] Dig Dis Sci. 1989 Jan;34(1):46-55 [2535980.001]
  • [Cites] Cancer Lett. 1992 Oct 30;67(1):79-86 [1423248.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jul 8;94(14):7356-61 [9207095.001]
  • [Cites] Surgery. 1997 Jul;122(1):82-90 [9225919.001]
  • [Cites] Am J Pathol. 1999 Apr;154(4):1223-9 [10233860.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Science. 2004 Nov 26;306(5701):1568-71 [15567866.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8492-5 [15574751.001]
  • [Cites] Int J Cancer. 2005 Jul 20;115(6):885-92 [15729726.001]
  • [Cites] Stem Cells. 2006 Mar;24(3):506-13 [16239320.001]
  • [Cites] J Cell Mol Med. 2006 Apr-Jun;10(2):292-308 [16796800.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1030-7 [17283135.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2007 Feb;6(1):92-7 [17287174.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):291-302 [17349585.001]
  • [Cites] Int J Cancer. 2007 Aug 15;121(4):699-705 [17534898.001]
  • [Cites] Ann Oncol. 2007 Jul;18(7):1268-79 [17488731.001]
  • [Cites] Pancreas. 2007 Oct;35(3):212-7 [17895840.001]
  • [Cites] Gastroenterology. 2007 Dec;133(6):1999-2009 [18054571.001]
  • [Cites] Am J Surg Pathol. 2001 May;25(5):579-86 [11342768.001]
  • (PMID = 19544970.001).
  • [ISSN] 0965-0407
  • [Journal-full-title] Oncology research
  • [ISO-abbreviation] Oncol. Res.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK058614-04; United States / NIDDK NIH HHS / DK / T32DK60443; United States / NIDDK NIH HHS / DK / R01 DK065096; United States / NIDDK NIH HHS / DK / R01 DK065096-06; United States / NIDDK NIH HHS / DK / DK065096-06; United States / NIDDK NIH HHS / DK / T32 DK060443-06; United States / NIDDK NIH HHS / DK / T32 DK060443; United States / NIDDK NIH HHS / DK / DK060443-06; United States / NIDDK NIH HHS / DK / R01 DK058614; United States / NIDDK NIH HHS / DK / R01 DK058614-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene; EC 3.1.3.48 / Antigens, CD45; EC 3.4.14.5 / Dipeptidyl Peptidase 4
  • [Other-IDs] NLM/ NIHMS81694; NLM/ PMC2762751
  •  go-up   go-down


33. Yango J, Pieters T, Coche E, Lambert M: [Increased serum CA 19.9 in bronchiectasis]. Rev Mal Respir; 2008 Jan;25(1):78-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Elévation du CA 19.9 sérique et bronchectasies.
  • INTRODUCTION: CA 19.9 is considered the most specific and sensitive serological marker of pancreatic adenocarcinoma.
  • Exhaustive investigation and clinical evolution excluded a neoplastic digestive disorder but positron emission tomography revealed a distinct hypermetabolic focus in the area of the hilum of the right lung.
  • [MeSH-major] Bronchiectasis / diagnosis. CA-19-9 Antigen / blood
  • [MeSH-minor] Aged. Biomarkers / blood. Female. Haemophilus Infections / diagnosis. Haemophilus Infections / immunology. Haemophilus influenzae / immunology. Haemophilus influenzae / isolation & purification. Humans

  • Genetic Alliance. consumer health - Bronchiectasis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18288056.001).
  • [ISSN] 0761-8425
  • [Journal-full-title] Revue des maladies respiratoires
  • [ISO-abbreviation] Rev Mal Respir
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Biomarkers; 0 / CA-19-9 Antigen
  •  go-up   go-down


34. Chen J, Röcken C, Nitsche B, Hosius C, Gschaidmeier H, Kahl S, Malfertheiner P, Ebert MP: The tyrosine kinase inhibitor imatinib fails to inhibit pancreatic cancer progression. Cancer Lett; 2006 Feb 28;233(2):328-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The tyrosine kinase inhibitor imatinib fails to inhibit pancreatic cancer progression.
  • Pancreatic cancers express KIT and PDGFRs.
  • Therefore, 26 patients with unresectable pancreatic cancer were randomized to either gemcitabine (1000 mg/m2 weekly) or imatinib (2x400 mg po) treatment daily.
  • Pancreatic adenocarcinoma was confirmed histologically and expression of KIT and PDGFRbeta was determined immunohistochemically in the biopsy specimens.
  • In this small series of pancreatic cancer patients, treatment with imatinib was not associated with a significant control of cancer progression.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Pancreatic Neoplasms / drug therapy. Piperazines / therapeutic use. Protein-Tyrosine Kinases / antagonists & inhibitors. Pyrimidines / therapeutic use
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / metabolism. Adenocarcinoma / secondary. Adult. Aged. Benzamides. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Disease Progression. Female. Humans. Imatinib Mesylate. Liver Neoplasms / drug therapy. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / metabolism. Lung Neoplasms / secondary. Male. Middle Aged. Proto-Oncogene Proteins c-kit / metabolism. Quality of Life. Receptors, Platelet-Derived Growth Factor / metabolism. Surveys and Questionnaires. Survival Rate

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15893416.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 0W860991D6 / Deoxycytidine; 8A1O1M485B / Imatinib Mesylate; B76N6SBZ8R / gemcitabine; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptors, Platelet-Derived Growth Factor
  •  go-up   go-down


35. Glazer ES, Zhu C, Massey KL, Thompson CS, Kaluarachchi WD, Hamir AN, Curley SA: Noninvasive radiofrequency field destruction of pancreatic adenocarcinoma xenografts treated with targeted gold nanoparticles. Clin Cancer Res; 2010 Dec 1;16(23):5712-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Noninvasive radiofrequency field destruction of pancreatic adenocarcinoma xenografts treated with targeted gold nanoparticles.
  • PURPOSE: Pancreatic carcinoma is one of the deadliest cancers with few effective treatments.
  • We used the astounding heating rates of AuNPs in nonionizing radiofrequency (RF) radiation to investigate human pancreatic xenograft destruction in a murine model.
  • EXPERIMENTAL DESIGN: Weekly, Panc-1 and Capan-1 human pancreatic carcinoma xenografts in immunocompromised mice were exposed to an RF field 36 hours after treatment (intraperitoneal) with cetuximab- or PAM4 antibody-conjugated AuNPs, respectively.
  • Cetuximab- and PAM4-conjugated AuNPs demonstrated RF field-induced destruction of Panc-1 and Capan-1 pancreatic carcinoma xenografts after 6 weeks of weekly treatment (P = 0.004 and P = 0.035, respectively).

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • Hazardous Substances Data Bank. GOLD, ELEMENTAL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3929S-37S [14506191.001]
  • [Cites] J Biomed Opt. 2000 Oct;5(4):383-90 [11092426.001]
  • [Cites] Cancer Res. 1979 Jun;39(6 Pt 2):2245-51 [445424.001]
  • [Cites] Ann Clin Lab Sci. 1981 Sep-Oct;11(5):386-91 [7036839.001]
  • [Cites] J Urol. 1989 Nov;142(5):1364-8 [2810532.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1990;416(4):343-9 [2106751.001]
  • [Cites] Am J Pathol. 1996 Oct;149(4):1271-86 [8863675.001]
  • [Cites] J Invest Dermatol. 1998 May;110(5):746-51 [9579539.001]
  • [Cites] Lasers Surg Med. 1998;23(4):194-203 [9829430.001]
  • [Cites] Langmuir. 2005 Nov 8;21(23):10644-54 [16262332.001]
  • [Cites] Hepatology. 2006 Feb;43(2 Suppl 1):S45-53 [16447274.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 12;103(50):18882-6 [17135351.001]
  • [Cites] J Clin Oncol. 2007 Nov 20;25(33):5225-32 [18024868.001]
  • [Cites] Cancer. 2007 Dec 15;110(12):2654-65 [17960610.001]
  • [Cites] Clin Cancer Res. 2007 Dec 15;13(24):7380-7 [18094420.001]
  • [Cites] Nat Protoc. 2008;3(2):314-20 [18274533.001]
  • [Cites] Biophys J. 2008 May 15;94(10):3790-7 [18234813.001]
  • [Cites] Cancer Res. 2008 Jun 15;68(12):4819-26 [18559529.001]
  • [Cites] Surgery. 2008 Aug;144(2):125-32 [18656617.001]
  • [Cites] J Exp Ther Oncol. 2008;7(4):313-26 [19227011.001]
  • [Cites] Ann Surg Oncol. 2009 Apr;16(4):836-47 [19194760.001]
  • [Cites] World J Gastroenterol. 2009 Jun 28;15(24):2995-3002 [19554652.001]
  • [Cites] Small. 2009 Jul;5(13):1553-61 [19326357.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Int J Radiat Biol. 2009 Dec;85(12):1114-25 [19995237.001]
  • [Cites] Adv Drug Deliv Rev. 2010 Mar 8;62(3):339-45 [19909777.001]
  • [Cites] J Surg Oncol. 2010 Mar 15;101(4):315-20 [20187063.001]
  • [Cites] Toxicol Appl Pharmacol. 2010 May 15;245(1):116-23 [20193702.001]
  • [Cites] Cancer. 2010 Jul 1;116(13):3285-93 [20564640.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13549-54 [14597719.001]
  • (PMID = 21138869.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / CA151668-02; United States / NCI NIH HHS / CA / T32 CA09599; United States / NCI NIH HHS / CA / CA016672; United States / NCI NIH HHS / CA / U54 CA151668; United States / NCI NIH HHS / CA / T32 CA009599-21; United States / NCI NIH HHS / CA / U54 CA143837; United States / NCI NIH HHS / CA / U54CA143837; United States / NCI NIH HHS / CA / U54 CA151668-02; United States / NCI NIH HHS / CA / T32 CA009599
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 7440-57-5 / Gold; PQX0D8J21J / Cetuximab
  • [Other-IDs] NLM/ NIHMS245136; NLM/ PMC3057504
  •  go-up   go-down


36. Wada K, Takada T, Amano H, Yoshida M, Miura F, Toyota N, Kato K, Isaka T, Nagashima I: [Trend in the management of pancreatic adenocarcinoma--Japan vs. US and Europe]. Nihon Geka Gakkai Zasshi; 2006 Jul;107(4):187-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Trend in the management of pancreatic adenocarcinoma--Japan vs. US and Europe].
  • Pancreatic adenocarcinoma remains to have poor prognosis.
  • Current rationale for the treatment of pancreatic adenocarcinoma in the US and European countries consists of the following formula:.
  • The efficacy of "Japanese" radical resection including vascular resection or pancreatic nerve plexus resection should be evaluated, although the devise of novel diagnostic modalities and more effective adjuvant or neoadjuvant therapy are crucial to improve prognosis of this disease.
  • [MeSH-major] Adenocarcinoma / therapy. Pancreatic Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16878412.001).
  • [ISSN] 0301-4894
  • [Journal-full-title] Nihon Geka Gakkai zasshi
  • [ISO-abbreviation] Nihon Geka Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 21
  •  go-up   go-down


37. Duffy A, Capanu M, Allen P, Kurtz R, Olson SH, Ludwig E, Klimstra DS, O'Reilly EM: Pancreatic adenocarcinoma in a young patient population--12-year experience at Memorial Sloan Kettering Cancer Center. J Surg Oncol; 2009 Jul 1;100(1):8-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic adenocarcinoma in a young patient population--12-year experience at Memorial Sloan Kettering Cancer Center.
  • BACKGROUND: There is a dearth of data in a younger population of patients with pancreatic ductal adenocarcinoma (PAC) regarding epidemiology, genetics, prognosis, and outcome.
  • RESULTS: One hundred thirty-six cases of PAC, age <or=45 years at diagnosis, were identified.
  • [MeSH-major] Adenocarcinoma / mortality. Pancreatic Neoplasms / mortality

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19384918.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Maluf-Filho F, Kumar A, Gerhardt R, Kubrusly M, Sakai P, Hondo F, Matuguma SE, Artifon E, Monteiro da Cunha JE, César Machado MC, Ishioka S, Forero E: Kras mutation analysis of fine needle aspirate under EUS guidance facilitates risk stratification of patients with pancreatic mass. J Clin Gastroenterol; 2007 Nov-Dec;41(10):906-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kras mutation analysis of fine needle aspirate under EUS guidance facilitates risk stratification of patients with pancreatic mass.
  • OBJECTIVES: The accuracy of endoscopic ultrasound-fine needle aspiration cytology (EUS-FNAC) for the diagnosis of pancreatic cancer is suboptimal.
  • Mutational activation of the kras oncogene is almost universally present in pancreatic cancer tissue.
  • We, therefore, investigated if analysis for mutant kras gene in the EUS-FNAC aspirates supplements cytopathology for the diagnosis of pancreatic adenocarcinoma (PAC).
  • METHODS: EUS-FNAC specimens obtained from 74 patients with pancreatic masses were analyzed for the presence of kras mutation on codon 12 using polymerase chain reaction-restriction fragment length polymorphism and MvaI restriction enzyme.
  • Definitive diagnosis was based on surgical pathology or long-term follow-up (median 27.8 mo); 57 patients had PAC, 11 patient's chronic pancreatitis, and 9 patient's nonfunctioning neuroendocrine tumors.
  • CONCLUSIONS: Analysis for the presence of mutant kras gene supplements conventional cytopathology for the diagnosis of PAC even without a cytopathologist in attendance and using only 3 needle passes.
  • Among patients with negative cytopathology, the presence of kras mutation represents pancreatic cancer while the absence of kras mutation increases the possibility of benign lesion.
  • [MeSH-major] Adenocarcinoma / diagnosis. Endosonography / methods. Mutation. Pancreas / pathology. Pancreatic Neoplasms / diagnosis. Proto-Oncogene Proteins / genetics. ras Proteins / genetics

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Gastroenterol. 2007 Nov-Dec;41(10):869-70 [18090153.001]
  • (PMID = 18090159.001).
  • [ISSN] 0192-0790
  • [Journal-full-title] Journal of clinical gastroenterology
  • [ISO-abbreviation] J. Clin. Gastroenterol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


39. Goulart BH, Clark JW, Lauwers GY, Ryan DP, Grenon N, Muzikansky A, Zhu AX: Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis. J Hematol Oncol; 2009;2:13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis.
  • BACKGROUND: Metastatic pancreatic adenocarcinoma has a short median overall survival (OS) of 5-6 months.
  • METHODS: We identified 20 patients with metastatic or recurrent pancreatic adenocarcinoma who received single-agent gemcitabine and had an OS longer than 1 year.
  • Baseline data available after the diagnosis of metastatic or recurrent disease was categorized as:.
  • CONCLUSION: A subgroup of patients with metastatic pancreatic cancer has prolonged survival after treatment with gemcitabine.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / rehabilitation. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / rehabilitation. Survivors

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2000 Mar;82(5):1013-6 [10737382.001]
  • [Cites] Am J Gastroenterol. 1999 May;94(5):1271-8 [10235206.001]
  • [Cites] Anticancer Res. 1999 Jul-Aug;19(4A):2433-5 [10470171.001]
  • [Cites] J Surg Oncol. 2000 Apr;73(4):212-8 [10797334.001]
  • [Cites] Oncol Rep. 2000 Jul-Aug;7(4):875-7 [10854561.001]
  • [Cites] Oncology. 2000 Nov;59(4):296-301 [11096341.001]
  • [Cites] J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79 [11307091.001]
  • [Cites] Acta Oncol. 2001;40(2-3):361-70 [11441941.001]
  • [Cites] Pancreas. 2002 Jan;24(1):15-25 [11741178.001]
  • [Cites] Am J Clin Oncol. 2001 Dec;24(6):547-50 [11801751.001]
  • [Cites] Cancer. 2002 Feb 15;94(4):902-10 [11920457.001]
  • [Cites] Br J Cancer. 2002 Jul 15;87(2):161-7 [12107836.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3270-5 [12149301.001]
  • [Cites] Int J Gastrointest Cancer. 2002;32(1):35-41 [12630768.001]
  • [Cites] Eur J Cancer. 2003 Jul;39(10):1377-83 [12826040.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3402-8 [12885837.001]
  • [Cites] Cancer. 2004 Jun 15;100(12):2664-70 [15197810.001]
  • [Cites] Cancer. 1974 Feb;33(2):563-7 [4812773.001]
  • [Cites] Cancer. 1978 Nov;42(5):2494-506 [363259.001]
  • [Cites] Med J Aust. 1981 Apr 4;1(7):361-3 [7242420.001]
  • [Cites] J Clin Oncol. 1991 Sep;9(9):1682-6 [1875224.001]
  • [Cites] J Clin Oncol. 1991 Dec;9(12):2128-33 [1960554.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] Digestion. 1997;58(6):503-7 [9438594.001]
  • [Cites] J Surg Oncol. 1998 Mar;67(3):151-9 [9530884.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • (PMID = 19291303.001).
  • [ISSN] 1756-8722
  • [Journal-full-title] Journal of hematology & oncology
  • [ISO-abbreviation] J Hematol Oncol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  • [Other-IDs] NLM/ PMC2663565
  •  go-up   go-down


40. Furukawa H, Uesaka K, Boku N: Treatment decision making in pancreatic adenocarcinoma: multidisciplinary team discussion with multidetector-row computed tomography. Arch Surg; 2008 Mar;143(3):275-80; discussion 281
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment decision making in pancreatic adenocarcinoma: multidisciplinary team discussion with multidetector-row computed tomography.
  • HYPOTHESIS: Multidetector-row computed tomography reduces the frequency of use of other imaging methods in patients with pancreatic carcinoma.
  • PATIENTS: Two hundred thirteen patients with pancreatic carcinoma.
  • MAIN OUTCOME MEASURE: Multidetector-row computed tomography was initially performed in patients with newly diagnosed pancreatic carcinoma.
  • RESULTS: Of the 213 pancreatic carcinomas, 79 (37%) were classified as probably resectable, 127 (60%) as certainly unresectable, and 7 (3%) as probably unresectable.
  • CONCLUSIONS: Multidetector-row computed tomography provides reliable information for staging pancreatic carcinoma.
  • Multidisciplinary team discussion along with use of this noninvasive technique simplifies the diagnostic strategy for pancreatic carcinoma and decreases the need for invasive staging methods.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / radiography. Decision Making. Pancreatic Neoplasms / radiography. Pancreatic Neoplasms / surgery. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18347275.001).
  • [ISSN] 1538-3644
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


41. Wargo JA, Warshaw AL: Surgical approach to pancreatic exocrine neoplasms. Minerva Chir; 2005 Dec;60(6):445-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical approach to pancreatic exocrine neoplasms.
  • Pancreatic exocrine neoplasms represent a wide spectrum of pathophysiologic entities that challenge us as surgeons.
  • In this review, we will explore the contemporary clinical management of pancreatic adenocarcinoma, acinar cell carcinoma, and cystic neoplasms of the pancreas.
  • [MeSH-major] Pancreas, Exocrine / surgery. Pancreatectomy. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / surgery. Algorithms. Carcinoma, Acinar Cell / surgery. Chemotherapy, Adjuvant. Cystadenocarcinoma / surgery. Cystadenoma / surgery. Decision Trees. Humans. Magnetic Resonance Imaging. Neoadjuvant Therapy / methods. Neoplasm Staging. Radiotherapy, Adjuvant. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16401999.001).
  • [ISSN] 0026-4733
  • [Journal-full-title] Minerva chirurgica
  • [ISO-abbreviation] Minerva Chir
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 181
  •  go-up   go-down


42. Nawroth R, van Zante A, Cervantes S, McManus M, Hebrok M, Rosen SD: Extracellular sulfatases, elements of the Wnt signaling pathway, positively regulate growth and tumorigenicity of human pancreatic cancer cells. PLoS One; 2007 Apr 25;2(4):e392
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extracellular sulfatases, elements of the Wnt signaling pathway, positively regulate growth and tumorigenicity of human pancreatic cancer cells.
  • Emerging evidence indicates the importance of reactivated Wnt signaling in a number of cancers, including pancreatic adenocarcinoma.
  • PRINCIPLE FINDINGS: Both Sulf proteins were upregulated in human pancreatic adenocarcinoma tumors and were broadly expressed in human pancreatic adenocarcinoma cell lines.
  • Three of four pancreatic adenocarcinoma cell lines tested exhibited autocrine Wnt signaling, in that extracellular Wnt ligands were required to initiate downstream Wnt signaling.
  • Exposure of these pancreatic adenocarcinoma cells to a catalytically inactive form of Sulf-2 or siRNA-mediated silencing of endogenous Sulf-2 inhibited both Wnt signaling and cell growth.
  • CONCLUSIONS/SIGNIFICANCE: We have identified the Sulfs as potentiators of autocrine Wnt signaling in pancreatic cancer cells and have demonstrated their contribution to the growth and tumorigenicity of these cells.
  • Since the Sulfs are extracellular enzymes, they would be attractive targets for therapy of pancreatic cancer.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7388-93 [11606367.001]
  • [Cites] Oncogene. 2004 Feb 19;23(7):1439-47 [14973553.001]
  • [Cites] Genes Cells. 2002 Feb;7(2):173-85 [11895481.001]
  • [Cites] J Biol Chem. 2002 Dec 20;277(51):49175-85 [12368295.001]
  • [Cites] Am J Pathol. 2003 Apr;162(4):1151-62 [12651607.001]
  • [Cites] Ann Surg Oncol. 2003 Apr;10(3):284-90 [12679314.001]
  • [Cites] J Cell Sci. 2003 Jul 1;116(Pt 13):2627-34 [12775774.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):6122-7 [15067127.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jul 13;101(28):10380-5 [15240889.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4717-20 [15256437.001]
  • [Cites] Oncogene. 2004 Aug 12;23(36):6170-4 [15208662.001]
  • [Cites] J Neurosci Res. 2004 Sep 1;77(5):653-61 [15352211.001]
  • [Cites] Cell. 1982 Nov;31(1):99-109 [6297757.001]
  • [Cites] Cancer Cell. 2004 Nov;6(5):497-506 [15542433.001]
  • [Cites] Development. 2004 Dec;131(24):6009-21 [15563523.001]
  • [Cites] Cancer Res. 2005 Feb 1;65(3):743-8 [15705870.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):843-50 [15829953.001]
  • [Cites] Mol Ther. 2005 May;11(5):724-33 [15851011.001]
  • [Cites] Mol Cancer. 2005;4(1):14 [15817123.001]
  • [Cites] Cancer Cell. 2005 May;7(5):469-83 [15894267.001]
  • [Cites] Nat Rev Cancer. 2005 Jun;5(6):459-67 [15905855.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6245-54 [16024626.001]
  • [Cites] J Biol Chem. 2005 Dec 2;280(48):40066-73 [16192265.001]
  • [Cites] Neoplasia. 2005 Nov;7(11):1001-10 [16331886.001]
  • [Cites] Dev Dyn. 2006 Mar;235(3):681-90 [16425220.001]
  • [Cites] J Biol Chem. 2006 Feb 24;281(8):4969-76 [16377625.001]
  • [Cites] BMC Biochem. 2006;7:2 [16417632.001]
  • [Cites] Neoplasia. 2006 Apr;8(4):279-89 [16756720.001]
  • [Cites] Gastroenterology. 2006 Jun;130(7):2130-44 [16762634.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6025-32 [16778174.001]
  • [Cites] Biochem J. 2006 Nov 15;400(1):63-73 [16901266.001]
  • [Cites] Mol Cell Biol. 2007 Jan;27(2):678-88 [17116694.001]
  • [Cites] Breast Cancer Res. 2006;8(5):R56 [17014703.001]
  • [Cites] Nat Genet. 2000 Jul;25(3):329-32 [10888884.001]
  • [Cites] J Clin Invest. 2001 Jul;108(2):169-73 [11457867.001]
  • [Cites] J Clin Invest. 2001 Aug;108(3):357-61 [11489926.001]
  • [Cites] J Biol Chem. 2001 Aug 17;276(33):30744-52 [11406624.001]
  • [Cites] Science. 2001 Aug 31;293(5535):1663-6 [11533491.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Jun 20;306(1):293-7 [12788103.001]
  • [Cites] J Biol Chem. 2003 Jun 20;278(25):23107-17 [12686563.001]
  • [Cites] J Cell Biol. 2003 Jul 21;162(2):341-51 [12860968.001]
  • [Cites] J Virol. 2003 Aug;77(16):8957-61 [12885912.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):846-51 [14520411.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):851-6 [14520413.001]
  • [Cites] Gene Expr. 2003;11(3-4):141-7 [14686787.001]
  • [Cites] Gastroenterology. 2004 Jan;126(1):231-48 [14699503.001]
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):903-11 [14737121.001]
  • [Cites] J Biol Chem. 2004 Feb 13;279(7):5604-11 [14645250.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13790-5 [11707567.001]
  • (PMID = 17460759.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL075602; United States / NIGMS NIH HHS / GM / GM57411; United States / NIGMS NIH HHS / GM / R01 GM057411; United States / NCI NIH HHS / CA / R21 CA122025; United States / NCI NIH HHS / CA / R01 CA112537; United States / NHLBI NIH HHS / HL / HL075602; United States / NCI NIH HHS / CA / CA122025; United States / NCI NIH HHS / CA / CA112537
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Wnt Proteins; EC 3.1.6.- / Sulfatases
  • [Other-IDs] NLM/ PMC1849966
  • [General-notes] NLM/ Original DateCompleted: 20070803
  •  go-up   go-down


43. Gregor JI, Heukamp I, Kilian M, Kiewert C, Schimke I, Kristiansen G, Walz MK, Jacobi CA, Wenger FA: Does enteral nutrition of dietary polyunsaturated fatty acids promote oxidative stress and tumour growth in ductal pancreatic cancer? Experimental trial in Syrian Hamster. Prostaglandins Leukot Essent Fatty Acids; 2006 Jan;74(1):67-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does enteral nutrition of dietary polyunsaturated fatty acids promote oxidative stress and tumour growth in ductal pancreatic cancer? Experimental trial in Syrian Hamster.
  • Thus we investigated the effects of n-3, n-6 and n-9 polyunsaturated fatty acids (PUFA) on oxidative stress (lipidperoxidation) and tumour growth in ductal pancreatic cancer.
  • 1, 3 and 5 received weekly subcutaneous (s.c.) injections of 10 mg N-nitrosobis-2-oxypropylamine (BOP)/kg body weight in order to induce ductal pancreatic adenocarcinoma.
  • Activities of glutathionperoxidase (GSH-Px), superoxiddismutase (SOD) and levels of lipidperoxidation were measured in samples of pancreatic carcinoma as well as in tumour-free pancreatic tissue.
  • RESULTS: While different diets did not significantly alter the overall incidence of histologically proven pancreatic adenocarcinoma, the number of macroscopically visible tumours was decreased in the FISH-OIL-gr.
  • CONCLUSION: Different diets did not significantly influence the incidence of histologically proven pancreatic adenocarcinoma.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / pathology. Dietary Fats, Unsaturated / pharmacology. Enteral Nutrition. Oxidative Stress / drug effects. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Animals. Carcinogens / administration & dosage. Carcinogens / toxicity. Cricetinae. Docosahexaenoic Acids / analysis. Docosahexaenoic Acids / pharmacology. Eicosapentaenoic Acid / analysis. Eicosapentaenoic Acid / pharmacology. Fatty Acids, Unsaturated / pharmacology. Fish Oils / chemistry. Fish Oils / pharmacology. Glutathione Peroxidase / metabolism. Linoleic Acid / analysis. Linoleic Acid / pharmacology. Male. Mesocricetus. Nitrosamines / administration & dosage. Nitrosamines / toxicity. Oleic Acid / analysis. Oleic Acid / pharmacology. Olive Oil. Pancreas / drug effects. Pancreas / metabolism. Pancreas / pathology. Plant Oils / chemistry. Plant Oils / pharmacology. Random Allocation. Soybean Oil / chemistry. Soybean Oil / pharmacology. Superoxide Dismutase / metabolism. Survival Rate. Thiobarbituric Acid Reactive Substances / metabolism. Triglycerides / chemistry. Triglycerides / pharmacology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. OLEIC ACID .
  • Hazardous Substances Data Bank. LINOLEIC ACID .
  • Hazardous Substances Data Bank. Soybean oil .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16226437.001).
  • [ISSN] 0952-3278
  • [Journal-full-title] Prostaglandins, leukotrienes, and essential fatty acids
  • [ISO-abbreviation] Prostaglandins Leukot. Essent. Fatty Acids
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Dietary Fats, Unsaturated; 0 / Fatty Acids, Unsaturated; 0 / Fish Oils; 0 / Nitrosamines; 0 / Olive Oil; 0 / Plant Oils; 0 / Thiobarbituric Acid Reactive Substances; 0 / Triglycerides; 25167-62-8 / Docosahexaenoic Acids; 2UMI9U37CP / Oleic Acid; 60599-38-4 / nitrosobis(2-oxopropyl)amine; 8001-22-7 / Soybean Oil; 9KJL21T0QJ / Linoleic Acid; AAN7QOV9EA / Eicosapentaenoic Acid; EC 1.11.1.9 / Glutathione Peroxidase; EC 1.15.1.1 / Superoxide Dismutase
  •  go-up   go-down


44. Sanchez SE, Trevino JG: Current adjuvant and targeted therapies for pancreatic adenocarcinoma. Curr Med Chem; 2008;15(17):1674-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current adjuvant and targeted therapies for pancreatic adenocarcinoma.
  • Pancreatic cancer is one of the deadliest malignancies, costing the lives of more than 30,000 patients every year.
  • Gemcitabine is currently considered to be the standard of care for the treatment of advanced pancreatic cancer.
  • In this paper we present an overview of the current treatment options for the different presenting stages of pancreatic cancer, including adjuvant, neoadjuvant, and targeted therapies, and attempt to provide a comprehensive analysis of the disparate research indicated on this front.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adjuvants, Pharmaceutic / therapeutic use. Pancreatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18673217.001).
  • [ISSN] 0929-8673
  • [Journal-full-title] Current medicinal chemistry
  • [ISO-abbreviation] Curr. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adjuvants, Pharmaceutic
  • [Number-of-references] 76
  •  go-up   go-down


45. Bilimoria KY, Bentrem DJ, Merkow RP, Tomlinson JS, Stewart AK, Ko CY, Talamonti MS: Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors. J Am Coll Surg; 2007 Oct;205(4):558-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors.
  • BACKGROUND: The American Joint Committee on Cancer (AJCC) 6(th) edition staging system for pancreatic adenocarcinoma specifically excludes pancreatic neuroendocrine tumors (PNETs), and a widely accepted staging classification does not exist.
  • Our objective was to evaluate the feasibility of applying the AJCC pancreatic adenocarcinoma staging system to PNETs.
  • When comparing outcomes to those of patients with pancreatic adenocarcinoma, the estimated median survival was significantly better for resected patients with PNETs (60 versus 13 months, p < 0.0001).
  • CONCLUSIONS: When applied to PNETs, the AJCC staging system for pancreatic adenocarcinoma provides survival discrimination by stage for surgical and nonsurgical patients.
  • Survival rates are better for PNETs than for pancreatic adenocarcinoma, but the staging system can effectively stratify patients with PNETs.
  • [MeSH-major] Neoplasm Staging. Neuroendocrine Tumors / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adolescent. Adult. Aged. Aged, 80 and over. Feasibility Studies. Female. Humans. Male. Middle Aged. Survival Analysis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17903729.001).
  • [ISSN] 1879-1190
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


46. Michaels PJ, Brachtel EF, Bounds BC, Brugge WR, Pitman MB: Intraductal papillary mucinous neoplasm of the pancreas: cytologic features predict histologic grade. Cancer; 2006 Jun 25;108(3):163-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary mucinous neoplasm of the pancreas: cytologic features predict histologic grade.
  • BACKGROUND: Intraductal papillary mucinous neoplasm (IPMN) is an increasingly recognized cystic neoplasm of the pancreas, histologically classified by the degree of epithelial atypia and by the presence or absence of invasion of the cyst wall.
  • METHODS: Thirty-three endoscopic ultrasound (EUS)-guided pancreatic fine-needle aspiration biopsy (FNAB) samples and 1 pancreatic duct brush specimen from 25 patients with a histologically confirmed IPMN were retrospectively reviewed.
  • These cytologic features were subsequently correlated with the histologic diagnosis.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / pathology. Mucins / metabolism. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16550572.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mucins
  •  go-up   go-down


47. Bao P, Potter D, Eisenberg DP, Lenzner D, Zeh HJ, Lee Iii KK, Hughes SJ, Sanders MK, Young JL, Moser AJ: Validation of a prediction rule to maximize curative (R0) resection of early-stage pancreatic adenocarcinoma. HPB (Oxford); 2009 Nov;11(7):606-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Validation of a prediction rule to maximize curative (R0) resection of early-stage pancreatic adenocarcinoma.
  • BACKGROUND: The surgeon's contribution to patients with localized pancreatic adenocarcinoma (PAC) is a margin negative (R0) resection.

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20495714.001).
  • [ISSN] 1477-2574
  • [Journal-full-title] HPB : the official journal of the International Hepato Pancreato Biliary Association
  • [ISO-abbreviation] HPB (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2785957
  •  go-up   go-down


48. Mihaljevic AL, Esposito I, Michalski CW, Kleeff J, Friess H: Defining new pancreatic tumour entities by molecular analysis. Pancreatology; 2009;9(4):334-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Defining new pancreatic tumour entities by molecular analysis.
  • Recent advances in molecular biology, biochemistry and genetics have broadened our understanding of tumourigenesis and of the maintenance and spread of pancreatic cancer far beyond traditional microscopic histopathological analysis.
  • While the main focus of pancreatic cancer research has been on pancreatic ductal adenocarcinoma, molecular research has also led to a better understanding of rare tumours of the pancreas, as well as to the definition of previously unknown tumour entities that can only be identified through the application of molecular tools.
  • Genetic and molecular approaches may, therefore, not only lead to a better understanding of the pathogenesis of pancreatic tumours, but also culminate in more precise diagnosis as well as individually tailored treatment strategies for affected patients.
  • [MeSH-major] Pancreatic Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma / classification. Adenocarcinoma / genetics. Humans. Molecular Biology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19451742.001).
  • [ISSN] 1424-3911
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 47
  •  go-up   go-down


49. Seicean A, Badea R, Stan-Iuga R, Mocan T, Gulei I, Pascu O: Quantitative contrast-enhanced harmonic endoscopic ultrasonography for the discrimination of solid pancreatic masses. Ultraschall Med; 2010 Dec;31(6):571-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative contrast-enhanced harmonic endoscopic ultrasonography for the discrimination of solid pancreatic masses.
  • PURPOSE: Contrast-enhanced harmonic endoscopic ultrasonography (CEH-EUS) for the assessment of microcirculation and the delineation of pancreatic tumors in order to characterize and stage them has only recently become available for commercial use, and few reports have been published.
  • The purpose of the study was the qualitative and quantitative digital image analysis of pancreatic adenocarcinomas using conventional endoscopic ultrasonography (EUS) and CEH-EUS and the evaluation of whether contrast medium injection modified adenocarcinoma staging and patient management.
  • MATERIALS AND METHODS: In each of 30 prospectively examined patients with suspected pancreatic solid lesions, CEH-EUS was performed using the same quantity of the contrast agent SonoVue and a low mechanical index (0.3 - 0.4), followed by EUS-FNA.
  • The histology, based on EUS-FNA or surgery and 9 months of follow-up, was: pancreatic adenocarcinoma (n = 15), pseudotumoral chronic pancreatitis (n = 12), neuroendocrine tumor (n = 1), common bile duct tumor (n = 1), lymph node metastases of gastric cancer (n = 1).
  • RESULTS: CEH-EUS showed a hypoenhanced pattern in 14 cases of adenocarcinoma and in 10 cases of chronic pancreatitis.
  • The index of the contrast uptake ratio was significantly lower in adenocarcinoma than in mass-forming chronic pancreatitis.
  • A cut-off uptake ratio index value of 0.17 for diagnosing adenocarcinoma corresponded to an AUC (CI 95%) of 0.86 (0.67 - 1.00) with a sensitivity of 80%, a specificity of 91.7%, a positive predictive value of 92.8%, and a negative predictive value of 78%.
  • The size of the pancreatic mass was assessed significantly more effectively by CEH-EUS but adenocarcinoma staging was not modified.
  • CONCLUSION: The majority of cases of both pancreatic adenocarcinoma and chronic pancreatitis were hypoenhanced and visual discrimination was not possible.
  • [MeSH-major] Adenocarcinoma / ultrasonography. Endosonography / methods. Image Enhancement / methods. Image Processing, Computer-Assisted / methods. Pancreatic Neoplasms / ultrasonography. Tumor Burden / physiology
  • [MeSH-minor] Aged. Aged, 80 and over. Biopsy. Contrast Media / administration & dosage. Diagnosis, Differential. Female. Humans. Male. Microvessels / ultrasonography. Middle Aged. Neoplasm Staging. Neovascularization, Pathologic / ultrasonography. Pancreatitis, Chronic / pathology. Pancreatitis, Chronic / ultrasonography. Phospholipids. Prospective Studies. Sulfur Hexafluoride

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. SULFUR HEXAFLUORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © Georg Thieme Verlag KG Stuttgart · New York.
  • (PMID = 21080306.001).
  • [ISSN] 1438-8782
  • [Journal-full-title] Ultraschall in der Medizin (Stuttgart, Germany : 1980)
  • [ISO-abbreviation] Ultraschall Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Phospholipids; 0 / contrast agent BR1; WS7LR3I1D6 / Sulfur Hexafluoride
  •  go-up   go-down


50. Eltoum IA, Eloubeidi MA, Chhieng DC, Tamhane A, Crowe R, Jhala D, St John KD, Wilcox CM, Siegal GP, Vickers S, Jhala NC: Cytologic grade independently predicts survival of patients with pancreatic adenocarcinoma. Am J Clin Pathol; 2005 Nov;124(5):697-707
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytologic grade independently predicts survival of patients with pancreatic adenocarcinoma.
  • Our objectives were to devise a cytologic grading system and determine whether it would predict survival of patients with solid-type pancreatic adenocarcinoma.
  • We devised a grading system that independently predicted survival in patients with pancreatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16203289.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Azure Stains; 0 / Romanowsky-Giemsa stain; TDQ283MPCW / Eosine Yellowish-(YS)
  •  go-up   go-down


51. Negi SS, Agarwal A, Chaudhary A: Flutamide in unresectable pancreatic adenocarcinoma: a randomized, double-blind, placebo-controlled trial. Invest New Drugs; 2006 May;24(3):189-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Flutamide in unresectable pancreatic adenocarcinoma: a randomized, double-blind, placebo-controlled trial.
  • PURPOSE: To evaluate the impact of flutamide on survival of patients with unresectable pancreatic cancer.
  • METHODS: This single institution, randomized, double-blind, placebo controlled study compared flutamide in the dose of 250 mg three times daily (n = 23) versus placebo (n = 23) in patients with histologically proven, previously untreated unresectable pancreatic adenocarcinoma.
  • CONCLUSIONS: Anti-androgen drug flutamide in the dose of 250 mg three times daily does not appear to prolong overall survival in unresectable pancreatic cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Androgen Antagonists / therapeutic use. Antineoplastic Agents, Hormonal / therapeutic use. Flutamide / therapeutic use. Pancreatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 1982 Oct;69(10):595-7 [7127040.001]
  • [Cites] BMJ. 1998 Jun 27;316(7149):1935-8 [9641928.001]
  • [Cites] Br Med J (Clin Res Ed). 1983 Jan 8;286(6359):93-5 [6401508.001]
  • [Cites] Br J Cancer. 1989 Nov;60(5):789-92 [2529892.001]
  • [Cites] Eur J Surg Oncol. 1986 Dec;12(4):321-4 [3536580.001]
  • [Cites] Br J Surg. 1990 Jul;77(7):725-30 [2200555.001]
  • [Cites] Eur J Surg Oncol. 1986 Mar;12(1):69-70 [3956756.001]
  • [Cites] Cancer. 1984 Feb 1;53(3 Suppl):630-43 [6692266.001]
  • [Cites] Eur J Surg Oncol. 1988 Jun;14(3):199-202 [3371470.001]
  • [Cites] Invest New Drugs. 1997;15(4):361-4 [9547680.001]
  • [Cites] Horm Metab Res. 1997 Mar;29(3):115-8 [9137981.001]
  • [Cites] Oncology. 1998 Dec;55 Suppl 1:17-22 [9852398.001]
  • [Cites] BMJ. 1999 Jan 30;318(7179):327-8 [10075464.001]
  • [Cites] Gastroenterology. 1986 Oct;91(4):1002-6 [3017803.001]
  • [Cites] Br J Surg. 1993 Mar;80(3):384-6 [8472160.001]
  • [Cites] Br J Cancer. 2002 Sep 23;87(7):716-9 [12232752.001]
  • [Cites] Int J Pancreatol. 1989 May;4(4):363-9 [2659684.001]
  • [Cites] Cancer Treat Rep. 1987 Jul-Aug;71(7-8):749-50 [3038316.001]
  • [Cites] Drugs Aging. 2000 Sep;17(3):161-3 [11043816.001]
  • [Cites] Cancer. 1986 May 15;57(10):1992-5 [3955505.001]
  • [Cites] Br J Cancer. 1992 Sep;66(3):503-6 [1520587.001]
  • [Cites] Eur J Surg Oncol. 1989 Jun;15(3):236-41 [2567682.001]
  • [Cites] Hepatogastroenterology. 1991 Apr;38(2):165-9 [1855775.001]
  • [Cites] Pancreas. 1987;2(6):684-7 [3438305.001]
  • (PMID = 16133790.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Antineoplastic Agents, Hormonal; 76W6J0943E / Flutamide
  •  go-up   go-down


52. Gbelcová H, Lenícek M, Zelenka J, Knejzlík Z, Dvoráková G, Zadinová M, Poucková P, Kudla M, Balaz P, Ruml T, Vítek L: Differences in antitumor effects of various statins on human pancreatic cancer. Int J Cancer; 2008 Mar 15;122(6):1214-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differences in antitumor effects of various statins on human pancreatic cancer.
  • The aim of the present study was to compare the effects of the individual commercially available statins on experimental pancreatic cancer.
  • The in vitro effects of individual statins (pravastatin, atorvastatin, simvastatin, lovastatin, cerivastatin, rosuvastatin and fluvastatin) on the viability of human pancreatic cancer were evaluated in CAPAN-2, BxPc-3 and MiaPaCa-2 cell lines.
  • In summary, substantial tumor-suppressive effects of various statins on the progression of experimental pancreatic adenocarcinoma were demonstrated, with marked differences among individual statins.
  • These results support greatly the potential of statins for the chemoadjuvant treatment of pancreatic cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology. Pancreatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Statins.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 18027870.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors
  •  go-up   go-down


53. Nakashima H, Nakamura M, Yamaguchi H, Yamanaka N, Akiyoshi T, Koga K, Yamaguchi K, Tsuneyoshi M, Tanaka M, Katano M: Nuclear factor-kappaB contributes to hedgehog signaling pathway activation through sonic hedgehog induction in pancreatic cancer. Cancer Res; 2006 Jul 15;66(14):7041-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nuclear factor-kappaB contributes to hedgehog signaling pathway activation through sonic hedgehog induction in pancreatic cancer.
  • In pancreatic cancer, pathway activation is reported to result from aberrant expression of the ligand, sonic Hh (Shh).
  • We hypothesized that nuclear factor-kappaB (NF-kappaB), a hallmark transcription factor in inflammatory responses, contributes to the overexpression of Shh in pancreatic cancer.
  • In the present study, we found a close positive correlation between NF-kappaB p65 and Shh expression in surgically resected pancreas specimens, including specimens of chronic pancreatitis and pancreatic adenocarcinoma.
  • We showed that blockade of NF-kappaB suppressed constitutive expression of Shh mRNA in pancreatic cancer cells.
  • NF-kappaB-induced Shh expression actually activated the Hh pathway in a ligand-dependent manner and enhanced cell proliferation in pancreatic cancer cells.
  • Our data suggest that NF-kappaB activation is one of the mechanisms underlying Shh overexpression in pancreatic cancer and that proliferation of pancreatic cancer cells is accelerated by NF-kappaB activation in part through Shh overexpression.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / metabolism. NF-kappa B / metabolism. Pancreatic Neoplasms / metabolism. Trans-Activators / biosynthesis

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16849549.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hedgehog Proteins; 0 / NF-kappa B; 0 / RNA, Messenger; 0 / SHH protein, human; 0 / Trans-Activators; 0 / Transcription Factor RelA
  •  go-up   go-down


54. Crnogorac-Jurcevic T, Gangeswaran R, Bhakta V, Capurso G, Lattimore S, Akada M, Sunamura M, Prime W, Campbell F, Brentnall TA, Costello E, Neoptolemos J, Lemoine NR: Proteomic analysis of chronic pancreatitis and pancreatic adenocarcinoma. Gastroenterology; 2005 Nov;129(5):1454-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic analysis of chronic pancreatitis and pancreatic adenocarcinoma.
  • BACKGROUND & AIMS: Markers to differentiate among pancreatic adenocarcinoma, chronic pancreatitis, and normal pancreas would be of significant clinical utility.
  • This study was therefore designed to analyze the proteome of such specimens and identify new candidate proteins for differential diagnosis.
  • METHODS: A PowerBlot analysis with more than 900 well-characterized antibodies was performed with tissue specimens from patients with chronic pancreatitis, pancreatic adenocarcinoma, and normal pancreas.
  • RESULTS: A total of 30 and 102 proteins showed significant deregulation between normal pancreas when compared with chronic pancreatitis and pancreatic adenocarcinoma, respectively, and although a substantial proportion were found similarly dysregulated in both chronic pancreatitis and pancreatic adenocarcinoma, several proteins were identified as potential disease-specific markers.
  • CONCLUSIONS: A large number of proteins are differentially expressed in chronic pancreatitis and pancreatic adenocarcinoma compared with normal pancreas.
  • [MeSH-major] Adenocarcinoma / physiopathology. Pancreatic Neoplasms / physiopathology. Pancreatitis, Chronic / physiopathology. Protein Array Analysis. Proteomics

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16285947.001).
  • [ISSN] 0016-5085
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


55. De Filippo M, Bocchi C, Quartieri L, Corradi D, Zompatori M: Mangafodipir-DPDP enhanced MRI visualization of a pancreatic adenocarcinoma previously undetected by extracellular contrast enhanced CT and MRI. Acta Biomed; 2007 Dec;78(3):225-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mangafodipir-DPDP enhanced MRI visualization of a pancreatic adenocarcinoma previously undetected by extracellular contrast enhanced CT and MRI.
  • We report a case of adenocarcinoma of the head of the pancreas, occult at extracellular contrast enhanced MDCT and magnetic resonance imaging (MRI), which was detected by MRI only with the use of a tissue-specific contrast agent (Mangafodipir trisodium Mn- DPDP).
  • The histological examination after duodenopancreatectomy confirmed the diagnosis.
  • Contrast-enhanced multi-detector computed tomography (MDCT) is currently considered to be the reference method for diagnosing and staging of pancreatic adenocarcinoma.
  • The technological evolution of magnetic resonance imaging and the development of organ-specific contrast media for liver and pancreas have led to a progressively more extensive use of this method for the investigation of suspected lesions.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / radiography. Contrast Media. Edetic Acid / analogs & derivatives. Magnetic Resonance Imaging / methods. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / radiography. Pyridoxal Phosphate / analogs & derivatives. Tomography, X-Ray Computed
  • [MeSH-minor] Cholangiopancreatography, Endoscopic Retrograde. Female. Humans. Middle Aged. Pancreas / pathology. Pancreaticoduodenectomy

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. Disodium EDTA .
  • Hazardous Substances Data Bank. ETHYLENEDIAMINE TETRAACETIC ACID .
  • Hazardous Substances Data Bank. DISODIUM CALCIUM EDTA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18330084.001).
  • [ISSN] 0392-4203
  • [Journal-full-title] Acta bio-medica : Atenei Parmensis
  • [ISO-abbreviation] Acta Biomed
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Contrast Media; 5V5IOJ8338 / Pyridoxal Phosphate; 9G34HU7RV0 / Edetic Acid; P28BIW0UTB / N,N'-bis(pyridoxal-5-phosphate)ethylenediamine-N,N'-diacetic acid
  •  go-up   go-down


56. Cisco R, Jeffrey RB, Norton JA: Solid pseudopapillary tumor of the pancreas: an unexpected finding after minor abdominal trauma. Dig Dis Sci; 2010 Feb;55(2):240-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solid pseudopapillary tumor of the pancreas: an unexpected finding after minor abdominal trauma.
  • [MeSH-major] Abdominal Injuries / diagnosis. Adenocarcinoma, Papillary / diagnosis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Biopsy, Fine-Needle. Colectomy. Diagnosis, Differential. Endosonography. Female. Gastrectomy. Humans. Pancreatectomy. Soccer / injuries. Splenectomy. Tomography, X-Ray Computed. Trauma Severity Indices. Young Adult

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2002 Jun;26(6):818-20 [12023593.001]
  • [Cites] World J Gastroenterol. 2008 Feb 14;14(6):960-5 [18240360.001]
  • [Cites] J Am Coll Surg. 2005 Jun;200(6):965-72 [15922212.001]
  • [Cites] Ann Surg Oncol. 2002 Jan-Feb;9(1):35-40 [11833495.001]
  • [Cites] Virchows Arch. 2000 May;436(5):473-80 [10881741.001]
  • [Cites] Pancreas. 2009 Apr;38(3):338; author reply 338-9 [19307928.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Jan;6(1):A22 [18166468.001]
  • [Cites] Arch Surg. 2008 Dec;143(12):1218-21 [19075175.001]
  • [Cites] J Surg Oncol. 2001 Apr;76(4):289-96 [11320522.001]
  • (PMID = 19890713.001).
  • [ISSN] 1573-2568
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Zhang B, Zhao WH, Zhou WY, Yu WS, Yu JM, Li S: Expression of vascular endothelial growth factors-C and -D correlate with evidence of lymphangiogenesis and angiogenesis in pancreatic adenocarcinoma. Cancer Detect Prev; 2007;31(6):436-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of vascular endothelial growth factors-C and -D correlate with evidence of lymphangiogenesis and angiogenesis in pancreatic adenocarcinoma.
  • BACKGROUND: We analyzed the intratumoral and peritumoral microvessel density (MVD) and microlymphatic vessel density (MLVD) in pancreatic adenocarcinoma (PAC) and recorded the expression of vascular endothelial growth factor (VEGF)-C and -D.
  • [MeSH-major] Adenocarcinoma / physiopathology. Lymphangiogenesis / physiology. Neovascularization, Pathologic / physiopathology. Pancreatic Neoplasms / physiopathology. Vascular Endothelial Growth Factor C / biosynthesis. Vascular Endothelial Growth Factor D / biosynthesis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18061373.001).
  • [ISSN] 1525-1500
  • [Journal-full-title] Cancer detection and prevention
  • [ISO-abbreviation] Cancer Detect. Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / VEGFC protein, human; 0 / Vascular Endothelial Growth Factor C; 0 / Vascular Endothelial Growth Factor D
  •  go-up   go-down


58. Tempero M, Arnoletti JP, Ben-Josef E, Bhargava P, Casper ES, Kim P, Malafa MP, Nakakura EK, Shibata S, Talamonti M, Wang H, Willett C: Pancreatic adenocarcinoma. Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw; 2007 Nov;5(10):998-1033
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic adenocarcinoma. Clinical Practice Guidelines in Oncology.
  • [MeSH-major] Adenocarcinoma. Pancreatic Neoplasms

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18053426.001).
  • [ISSN] 1540-1405
  • [Journal-full-title] Journal of the National Comprehensive Cancer Network : JNCCN
  • [ISO-abbreviation] J Natl Compr Canc Netw
  • [Language] eng
  • [Publication-type] Journal Article; Practice Guideline; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  • [Number-of-references] 196
  •  go-up   go-down


59. Schmitz-Winnenthal FH, Galindo-Escobedo LV, Rimoldi D, Geng W, Romero P, Koch M, Weitz J, Krempien R, Niethammer AG, Beckhove P, Buchler MW, Z'graggen K: Potential target antigens for immunotherapy in human pancreatic cancer. Cancer Lett; 2007 Jul 18;252(2):290-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential target antigens for immunotherapy in human pancreatic cancer.
  • Still very little is known about the expression of tumor-related antigens in pancreatic neoplasms.
  • METHODS: Pancreatic adenocarcinoma tumor samples (n=130) were obtained intraoperatively, control tissues (n=23) were collected from cadaveric donor and from patients with chronic pancreatitis.
  • Sequencing of PCR products were performed to assess the expression of SSX-4 in neoplastic and normal pancreatic tissues.
  • RESULTS: Three of 10 tested antigens were expressed in over 10% of malignant pancreatic tissue samples.
  • No expression of CT antigens was found in non-malignant pancreatic tissue with the exception of SSX-4 and and SSX-2.
  • The concomitant expression of SSX-4 in both malignant and non-malignant pancreatic tissue is a new finding which may raise concerns for immunotherapy.
  • However, HERV-K-MEL is expressed with a relatively high prevalence and may be a candidate for specific immunotherapy in a large subgroup of pancreatic cancer patients.
  • [MeSH-major] Adenocarcinoma / therapy. Antigens, Neoplasm / immunology. Immunotherapy. Pancreatic Neoplasms / therapy

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17320278.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA Primers; M801H13NRU / Azacitidine
  •  go-up   go-down


60. Förster GJ, Santos EB, Smith-Jones PM, Zanzonico P, Larson SM: Pretargeted radioimmunotherapy with a single-chain antibody/streptavidin construct and radiolabeled DOTA-biotin: strategies for reduction of the renal dose. J Nucl Med; 2006 Jan;47(1):140-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A human pancreatic adenocarcinoma xenograft model (HPAC) in nude mice was used.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / radiotherapy. Biotin / analogs & derivatives. Drug Delivery Systems / methods. Gallium Radioisotopes / pharmacokinetics. Kidney / metabolism. Organometallic Compounds / pharmacokinetics. Radioimmunotherapy / methods

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BIOTIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16391198.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1R2CA83084; United States / NCRR NIH HHS / RR / S10-RR017935
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DOTA-biotin; 0 / Gallium Radioisotopes; 0 / Immunoglobulin Fragments; 0 / Organometallic Compounds; 0 / Radiopharmaceuticals; 6SO6U10H04 / Biotin; 9013-20-1 / Streptavidin
  •  go-up   go-down


61. Manzanet G, Suelves C, Trías A, Calderón R, Morón R, Corell R, Navarro J, Clarós A, Peiró E, Todolí G, Castell L: [Cephalic pancreaticoduodenectomy with mesentericoportal venous reconstruction. Technical features]. Cir Esp; 2006 Aug;80(2):105-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cephalic pancreaticoduodenectomy (CPD) with mesentericoportal venous resection increases the resectability rate of pancreatic tumors.
  • We present a case of adenocarcinoma of the pancreatic head infiltrating the superior mesenteric-portal vein confluence that underwent surgery in our hospital.
  • [MeSH-major] Adenocarcinoma / surgery. Mesenteric Veins / surgery. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy / methods. Portal Vein / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16945309.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


62. Gesierich S, Paret C, Hildebrand D, Weitz J, Zgraggen K, Schmitz-Winnenthal FH, Horejsi V, Yoshie O, Herlyn D, Ashman LK, Zöller M: Colocalization of the tetraspanins, CO-029 and CD151, with integrins in human pancreatic adenocarcinoma: impact on cell motility. Clin Cancer Res; 2005 Apr 15;11(8):2840-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colocalization of the tetraspanins, CO-029 and CD151, with integrins in human pancreatic adenocarcinoma: impact on cell motility.
  • PURPOSE: Patients with pancreatic adenocarcinoma have a poor prognosis due to the extraordinary high invasive capacity of this tumor.
  • We recently reported that after protein kinase C activation, colocalization of alpha6beta4 with the tetraspanin CO-029 strongly supports migration of a rat pancreatic adenocarcinoma.
  • The finding led us to explore whether and which integrin-tetraspanin complexes influence the motility of human pancreatic tumors.
  • EXPERIMENTAL DESIGN: Integrin and tetraspanin expression of pancreatic and colorectal adenocarcinoma was evaluated with emphasis on colocalization and the impact of integrin-tetraspanin associations on tumor cell motility.
  • RESULTS: The majority of pancreatic and colorectal tumors expressed the alpha2, alpha3, alpha6, beta1, and beta4 integrins and the tetraspanins CD9, CD63, CD81, CD151, and CO-029.
  • CD63, CD81, and beta1 expression was observed at comparably high levels in healthy pancreatic tissue. alpha3beta1 frequently colocalized and coimmunoprecipitated with CD9, CD81, and CD151, whereas alpha6beta4 colocalized and coimmunoprecipitated mostly with CD151 and CO-029.
  • CONCLUSION: alpha6beta4 is selectively up-regulated in pancreatic and colorectal cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Membrane Proteins / analysis. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15837731.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD151; 0 / Antigens, Neoplasm; 0 / CD151 protein, human; 0 / Cd151 protein, rat; 0 / Integrins; 0 / Membrane Glycoproteins; 0 / Membrane Proteins; 0 / TSPAN8 protein, human; 0 / Tetraspanins
  •  go-up   go-down


63. Pawlik TM, Abdalla EK, Barnett CC, Ahmad SA, Cleary KR, Vauthey JN, Lee JE, Evans DB, Pisters PW: Feasibility of a randomized trial of extended lymphadenectomy for pancreatic cancer. Arch Surg; 2005 Jun;140(6):584-9; discussion 589-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feasibility of a randomized trial of extended lymphadenectomy for pancreatic cancer.
  • HYPOTHESIS: The required sample size of a prospective randomized trial comparing standard pancreaticoduodenectomy with pancreaticoduodenectomy plus extended lymphadenectomy for pancreatic adenocarcinoma is prohibitively large, making such a trial infeasible.
  • PATIENTS: We identified 158 patients who underwent pancreaticoduodenectomy for pancreatic adenocarcinoma with separate pathologic analysis of second-echelon lymph nodes, defined as lymph nodes along the proximal hepatic artery and/or the great vessels.
  • [MeSH-major] Adenocarcinoma / surgery. Lymph Node Excision. Pancreatic Neoplasms / surgery. Randomized Controlled Trials as Topic

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15967906.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Chang YT, Chang MC, Wei SC, Tien YW, Hsu C, Liang PC, Tsao PN, Jan IS, Wong JM: Serum vascular endothelial growth factor/soluble vascular endothelial growth factor receptor 1 ratio is an independent prognostic marker in pancreatic cancer. Pancreas; 2008 Aug;37(2):145-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum vascular endothelial growth factor/soluble vascular endothelial growth factor receptor 1 ratio is an independent prognostic marker in pancreatic cancer.
  • We sought to determine the role of pretreated serum angiogenic factors, including vascular endothelial growth factor (VEGF), placental growth factor (PlGF), and soluble vascular endothelial growth factor receptor 1 (sVEGFR-1), in predicting clinical outcome in patients with pancreatic cancer.
  • METHODS: We assessed pretreated serum VEGF, PlGF, and sVEGFR-1 levels in 92 patients with pancreatic adenocarcinoma and 60 healthy control subjects using an enzyme-linked immunosorbent assay.
  • RESULTS: Serum levels of VEGF, PlGF, and sVEGFR-1 were significantly higher in patients with pancreatic cancer compared with those in controls (583.8 +/- 559.5 vs 187.63 +/- 393.32, 17.65 +/- 7.34 vs 10.93 +/- 1.21, and 50.94 +/- 51.17 vs 15.55 +/- 1.98 pg/mL, respectively; P < 0.0001).
  • Cox regression analysis showed that the VEGF/sVEGFR-1 ratio was an independent predictor for pancreatic cancer survival.
  • Higher VEGF/sVEGFR-1 ratio was significantly correlated with poor outcome in patents with pancreatic cancer.
  • CONCLUSIONS: Vascular endothelial growth factor/sVEGF-1 ratio is an independent prognostic factor for survival in pancreatic cancer.
  • Its significance should be assessed when considering antiangiogenic therapy in treating pancreatic cancer patients.
  • [MeSH-major] Adenocarcinoma / blood. Pancreatic Neoplasms / blood. Vascular Endothelial Growth Factor A / blood. Vascular Endothelial Growth Factor Receptor-1 / blood

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Pancreatic cancer 1.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18665074.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Pregnancy Proteins; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 144589-93-5 / placenta growth factor; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1
  •  go-up   go-down


65. Muslimov GF: Role of epidermal growth factor gene in the development of pancreatic cancer and efficiency of inhibitors of this gene in the treatment of pancreatic carcinoma. Bull Exp Biol Med; 2008 Apr;145(4):535-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of epidermal growth factor gene in the development of pancreatic cancer and efficiency of inhibitors of this gene in the treatment of pancreatic carcinoma.
  • The expression of epidermal growth factor receptors in normal and tumor cells of the pancreas, the type and incidence of EGFR gene polymorphism were studied.
  • EGFR gene expression in pancreatic adenocarcinoma cells significantly surpassed that in normal pancreatic cells.
  • On the other hand, AA genome and A allele polymorphism in the EGF gene nucleotide pair G-A 61 is a significant risk factor for pancreatic cancer.
  • The effect of AG-1478 preparation (a new-generation inhibitor of EGFR) on apoptosis and cell proliferation in pancreatic cancer was evaluated.
  • [MeSH-major] Carcinoma / drug therapy. Epidermal Growth Factor / physiology. Pancreatic Neoplasms / drug therapy. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Tyrphostins / therapeutic use

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19110611.001).
  • [ISSN] 0007-4888
  • [Journal-full-title] Bulletin of experimental biology and medicine
  • [ISO-abbreviation] Bull. Exp. Biol. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; 0 / Tyrphostins; 170449-18-0 / tyrphostin AG 1478; 62229-50-9 / Epidermal Growth Factor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; U3P01618RT / Fluorouracil
  •  go-up   go-down


66. Klos D, Lovecek M, Srovnal J, Benedíková A, Růzková V, Radová L, Hajdúch M, Neoral C, Havlík R: [Possibility of using the determination of minimal residual disease in pancreatic adenocarcinoma using real-time RT-PCR--a pilot study]. Cas Lek Cesk; 2010;149(2):69-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Possibility of using the determination of minimal residual disease in pancreatic adenocarcinoma using real-time RT-PCR--a pilot study].
  • BACKGROUND: Minimal residual disease in patients with pancreatic cancer is defined as the presence of isolated tumor cells in the patient's body, in which the primary tumor was removed and is currently without clinical signs of disease.
  • METHODS AND RESULTS; The study to date included 70 patients operated on with curative intent for carcinoma of the pancreas.
  • CONCLUSIONS: The results of this pilot study demonstrated a high sensitivity and specificity of the RT-PCR method for detecting circulating tumor cells in patients with pancreatic cancer.
  • By utilizing this methodology, we are able to provide prognostic value of minimal residual disease and its significance for the indication of radical surgery for pancreatic cancer.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / analysis. Carcinoembryonic Antigen / analysis. Pancreatic Neoplasms / diagnosis. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20662469.001).
  • [ISSN] 0008-7335
  • [Journal-full-title] Casopís lékar̆ů c̆eských
  • [ISO-abbreviation] Cas. Lek. Cesk.
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


67. Yoong W, Subba B, Youssef I, Ojo K, Jarvis K: Pancreatic adenocarcinoma: a cause of elevated serum beta HCG. J Obstet Gynaecol; 2005 Jan;25(1):89-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic adenocarcinoma: a cause of elevated serum beta HCG.
  • [MeSH-major] Adenocarcinoma / blood. Chorionic Gonadotropin, beta Subunit, Human / blood. Pancreatic Neoplasms / blood

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16147719.001).
  • [ISSN] 0144-3615
  • [Journal-full-title] Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology
  • [ISO-abbreviation] J Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin, beta Subunit, Human
  •  go-up   go-down


68. Nakata K, Nagai E, Ohuchida K, Hayashi A, Miyasaka Y, Aishima S, Oda Y, Mizumoto K, Tanaka M, Tsuneyoshi M: S100P is a novel marker to identify intraductal papillary mucinous neoplasms. Hum Pathol; 2010 Jun;41(6):824-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intraductal papillary mucinous neoplasms of the pancreas are subclassified based on morphological features, and different immunohistochemical profiles have been identified in association with the subtypes.
  • We previously reported that S100P was an early developmental marker of pancreatic carcinogenesis and that there was higher S100P expression in intraductal papillary mucinous neoplasms than in normal pancreatic ductal epithelium.
  • S100P expression was not detected in normal pancreatic ductal epithelium but was detected in all intraductal papillary mucinous neoplasm cells (100%) with diffuse nuclear or nuclear/cytoplasmic staining.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Biomarkers, Tumor / biosynthesis. Calcium-Binding Proteins / biosynthesis. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Papillary / diagnosis. Neoplasm Proteins / biosynthesis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Aged. Aged, 80 and over. Diagnosis, Differential. Epithelium / metabolism. Epithelium / pathology. Female. Humans. Immunohistochemistry. Male. Middle Aged. Mucin 5AC / biosynthesis. Mucin-1 / biosynthesis. Mucin-2 / biosynthesis. Neoplasm Invasiveness. Pancreas / metabolism. Pancreas / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20153506.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Calcium-Binding Proteins; 0 / MUC1 protein, human; 0 / MUC2 protein, human; 0 / MUC5AC protein, human; 0 / Mucin 5AC; 0 / Mucin-1; 0 / Mucin-2; 0 / Neoplasm Proteins; 0 / S100P protein, human
  •  go-up   go-down


69. Meyer JJ, Willett CG, Czito BG: Is there a role for advanced radiation therapy technologies in the treatment of pancreatic adenocarcinoma? Future Oncol; 2008 Apr;4(2):241-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is there a role for advanced radiation therapy technologies in the treatment of pancreatic adenocarcinoma?
  • Pancreatic cancer remains a highly challenging problem in oncology.
  • Radiation continues to play a role in the treatment of pancreatic cancer, in both the adjuvant and locally advanced settings.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Pancreatic Neoplasms / radiotherapy. Radiotherapy / methods


70. Kuemmerle A, Decosterd LA, Buclin T, Liénard D, Stupp R, Chassot PG, Mosimann F, Lejeune F: A phase I pharmacokinetic study of hypoxic abdominal stop-flow perfusion with gemcitabine in patients with advanced pancreatic cancer and refractory malignant ascites. Cancer Chemother Pharmacol; 2009 Jan;63(2):331-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I pharmacokinetic study of hypoxic abdominal stop-flow perfusion with gemcitabine in patients with advanced pancreatic cancer and refractory malignant ascites.
  • PURPOSE: As no curative treatment for advanced pancreatic and biliary cancer with malignant ascites exists, new modalities possibly improving the response to available chemotherapies must be explored.
  • This phase I study assesses the feasibility, tolerability and pharmacokinetics of a regional treatment of gemcitabine administered in escalating doses by the stop-flow approach to patients with advanced abdominal malignancies (adenocarcinoma of the pancreas, n = 8, and cholangiocarcinoma of the liver, n = 1).
  • CONCLUSIONS: Regional exposure to gemcitabine-the current standard drug for advanced adenocarcinoma of the pancreas-can be markedly enhanced using an optimised hypoxic stop-flow perfusion technique, with acceptable toxicities up to a dose of 1,125 mg/m(2).
  • [MeSH-major] Anoxia. Antimetabolites, Antineoplastic / pharmacokinetics. Ascites / drug therapy. Deoxycytidine / analogs & derivatives. Drug Delivery Systems / methods. Pancreatic Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18587581.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


71. Artinyan A, Soriano PA, Prendergast C, Low T, Ellenhorn JD, Kim J: The anatomic location of pancreatic cancer is a prognostic factor for survival. HPB (Oxford); 2008;10(5):371-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The anatomic location of pancreatic cancer is a prognostic factor for survival.
  • BACKGROUND: Pancreatic cancers of the body and tail (BT) appear to have poorer survival compared with head (HD) lesions.
  • METHODS: The Surveillance, Epidemiology, and End Results registry identified 33,752 patients with pancreatic adenocarcinoma and 6443 patients who underwent cancer-directed surgery between 1988 and 2004.
  • DISCUSSION: Pancreatic BT cancers have a lower rate of resectability and poorer overall survival compared to HD lesions.
  • Prospective large-cohort studies may definitively prove that tumor location is a prognostic factor for survival in patients with pancreatic cancer.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pancreas. 2008 Jul;37(1):19-24 [18580439.001]
  • [Cites] CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33 [10735013.001]
  • [Cites] J Am Coll Surg. 2008 Mar;206(3):451-7 [18308215.001]
  • [Cites] BMC Cancer. 2008;8:5 [18194510.001]
  • [Cites] Arch Surg. 2007 Aug;142(8):767-723; discussion 773-4 [17709731.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] J Gastrointest Surg. 2006 Nov;10(9):1199-210; discussion 1210-1 [17114007.001]
  • [Cites] Ann Surg Oncol. 2006 Sep;13(9):1189-200 [16955385.001]
  • [Cites] Curr Opin Gastroenterol. 2006 Sep;22(5):520-6 [16891883.001]
  • [Cites] Ann Surg. 2006 Jul;244(1):10-5 [16794383.001]
  • [Cites] J Gastrointest Surg. 2005 Sep-Oct;9(7):922-7 [16137585.001]
  • [Cites] Br J Cancer. 2005 Apr 25;92(8):1372-81 [15812554.001]
  • [Cites] Ann Surg. 1998 Oct;228(4):508-17 [9790340.001]
  • [Cites] Ann Surg. 1996 May;223(5):506-11; discussion 511-2 [8651741.001]
  • [Cites] Ann Surg. 1995 Jan;221(1):59-66 [7826162.001]
  • [Cites] Am J Surg. 1993 Jan;165(1):68-72; discussion 72-3 [8380315.001]
  • [Cites] Cancer. 1985 Jul 15;56(2):397-402 [4005804.001]
  • [Cites] Cancer. 1990 Jul 1;66(1):56-61 [2354408.001]
  • [Cites] Pancreas. 2004 Mar;28(2):160-5 [15028948.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1200-10 [15028824.001]
  • [Cites] Am J Surg. 2003 May;185(5):476-80 [12727570.001]
  • [Cites] World J Surg. 2002 Nov;26(11):1309-14 [12297922.001]
  • [Cites] Ann Surg. 2002 Sep;236(3):355-66; discussion 366-8 [12192322.001]
  • [Cites] J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79 [11307091.001]
  • [Cites] Arch Surg. 2001 Apr;136(4):391-8 [11296108.001]
  • [Cites] Dig Surg. 2008;25(1):32-8 [18292659.001]
  • (PMID = 18982154.001).
  • [ISSN] 1365-182X
  • [Journal-full-title] HPB : the official journal of the International Hepato Pancreato Biliary Association
  • [ISO-abbreviation] HPB (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2575681
  • [Keywords] NOTNLM ; SEER / pancreatic cancer / tumor location
  •  go-up   go-down


72. Li D, Liu H, Jiao L, Chang DZ, Beinart G, Wolff RA, Evans DB, Hassan MM, Abbruzzese JL: Significant effect of homologous recombination DNA repair gene polymorphisms on pancreatic cancer survival. Cancer Res; 2006 Mar 15;66(6):3323-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significant effect of homologous recombination DNA repair gene polymorphisms on pancreatic cancer survival.
  • We investigated the effect of six single nucleotide polymorphisms of the RecQ1, RAD54L, XRCC2, and XRCC3 genes on overall survival of 378 patients with pancreatic adenocarcinoma who were treated at University of Texas M.D.
  • Survival was determined from pathologic diagnosis to death.
  • These observations suggest that polymorphisms of genes involved in the repair of DNA double-strand breaks significantly affect the clinical outcome of patients with pancreatic cancer.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Mol Genet. 2004 Jan 15;13(2):203-12 [14645207.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8181-7 [14678973.001]
  • [Cites] J Clin Oncol. 2004 Jul 1;22(13):2594-601 [15173214.001]
  • [Cites] J Cell Biochem. 2004 Oct 15;93(3):429-36 [15372620.001]
  • [Cites] Curr Biol. 1996 Jul 1;6(7):828-38 [8805304.001]
  • [Cites] Cell. 1997 Apr 18;89(2):195-204 [9108475.001]
  • [Cites] Cancer Res. 1997 Jun 15;57(12):2378-83 [9192813.001]
  • [Cites] Semin Oncol. 1997 Apr;24(2 Suppl 7):S7-24-S7-28 [9194476.001]
  • [Cites] Mol Cell. 1998 May;1(6):783-93 [9660962.001]
  • [Cites] Int J Radiat Biol. 1998 May;73(5):511-20 [9652808.001]
  • [Cites] Somat Cell Mol Genet. 1997 Jul;23(4):237-47 [9542526.001]
  • [Cites] Oncogene. 1999 Jun 3;18(22):3427-30 [10362365.001]
  • [Cites] Nat Rev Drug Discov. 2005 Jun;4(6):500-9 [15915153.001]
  • [Cites] J Biol Chem. 2005 Jul 29;280(30):28085-94 [15886194.001]
  • [Cites] J Biol Chem. 2005 Jul 29;280(30):28072-84 [15899892.001]
  • [Cites] Genes Dev. 1999 Oct 15;13(20):2633-8 [10541549.001]
  • [Cites] Mol Cell Biol. 2000 May;20(9):3147-56 [10757799.001]
  • [Cites] Anticancer Drugs. 2000 Nov;11(10):771-86 [11142685.001]
  • [Cites] Nat Genet. 2001 Mar;27(3):247-54 [11242102.001]
  • [Cites] Hum Mol Genet. 2001 Apr;10(7):741-6 [11257107.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2649-55 [11289143.001]
  • [Cites] Q J Nucl Med. 2000 Dec;44(4):355-64 [11302264.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8454-60 [11459989.001]
  • [Cites] Cancer Res. 2001 Dec 15;61(24):8654-8 [11751380.001]
  • [Cites] Hum Mol Genet. 2002 Jun 1;11(12):1433-8 [12023985.001]
  • [Cites] Oncogene. 2002 Jun 13;21(26):4176-80 [12037675.001]
  • [Cites] J Natl Cancer Inst. 2002 Jul 17;94(14):1091-9 [12122100.001]
  • [Cites] Biochem Pharmacol. 2003 Jan 15;65(2):275-82 [12504803.001]
  • [Cites] Semin Radiat Oncol. 2003 Jan;13(1):13-21 [12520460.001]
  • [Cites] J Biol Chem. 2003 Jan 17;278(3):1424-32 [12419808.001]
  • [Cites] Nat Rev Cancer. 2003 Mar;3(3):169-78 [12612652.001]
  • [Cites] BMC Cancer. 2003 Mar 4;3:6 [12614485.001]
  • [Cites] Mol Cell Biol. 2003 May;23(10):3527-35 [12724411.001]
  • [Cites] Lung Cancer. 2003 Aug;41 Suppl 1:S97-102 [12867068.001]
  • [Cites] Trends Cell Biol. 2003 Sep;13(9):493-501 [12946629.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Oct 1;57(2):553-62 [12957269.001]
  • [Cites] Genes Dev. 2004 Mar 15;18(6):602-16 [15075289.001]
  • (PMID = 16540687.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R03 CA084581; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / CA16672; United States / NCI NIH HHS / CA / P20 CA101936; United States / NCI NIH HHS / CA / R01 CA098380
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / RAD54L protein, human; 0 / X-ray repair cross complementing protein 3; 0 / XRCC2 protein, human; EC 3.6.1.- / Adenosine Triphosphatases; EC 3.6.1.- / RECQL protein, human; EC 3.6.4.- / DNA Helicases; EC 3.6.4.12 / RecQ Helicases
  • [Other-IDs] NLM/ NIHMS7848; NLM/ PMC1462866
  •  go-up   go-down


73. Seelig MH, Chromik AM, Weyhe D, Müller CA, Belyaev O, Mittelkötter U, Tannapfel A, Uhl W: Pancreatic redo procedures: to do or not to do -- this is the question. J Gastrointest Surg; 2007 Sep;11(9):1175-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic redo procedures: to do or not to do -- this is the question.
  • BACKGROUND: Pancreatic redo procedures belong to the most difficult abdominal operations because of altered anatomy, significant adhesions, and the potential of recurrent disease.
  • We report on our experience with 15 redo procedures among a series of 350 consecutive pancreatic operations.
  • PATIENT AND METHODS: From January 1, 2004 to May 31, 2006 a total of 350 patients underwent pancreatic surgery in our department.
  • There were 15 patients identified who had pancreatic redo surgery for benign (14) or malignant (1) disease.
  • Perioperative parameters and outcome of 15 patients undergoing redo surgery after pancreatic resections were evaluated.
  • RESULTS: Operative procedures included revision and redo of the pancreaticojejunostomy after resection of the pancreatic margin (6), completion pancreatectomy (3), conversion from duodenum-preserving pancreatic head resection to pylorus-preserving pancreaticoduodenectomy (3), classic pancreaticoduodenectomy after nonresective pancreatic surgery (1), redo of left-sided pancreatectomy (1), and classic pancreaticoduodenectomy after left-sided pancreatectomy (1).
  • Histology revealed chronic pancreatitis in 14 and a mucinous adenocarcinoma of the pancreas in 1 patient.
  • CONCLUSION: Pancreatic redo surgery can be performed with low morbidity and mortality.
  • [MeSH-major] Digestive System Surgical Procedures. Pancreatic Neoplasms / surgery. Pancreatitis, Chronic / surgery
  • [MeSH-minor] Adult. Constriction, Pathologic. Cystadenocarcinoma / surgery. Female. Gastroenterostomy. Humans. Jejunum / pathology. Magnetic Resonance Imaging. Male. Middle Aged. Pancreatic Ducts / pathology. Pancreaticoduodenectomy. Pancreaticojejunostomy. Reoperation

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1994 Feb;219(2):211-21 [7907464.001]
  • [Cites] Ann Surg. 2006 May;243(5):673-80; discussion 680-3 [16633003.001]
  • [Cites] Chirurg. 1980 May;51(5):303-7 [7408575.001]
  • [Cites] Pancreas. 1987;2(6):701-7 [3438308.001]
  • [Cites] Ann Surg. 2002 Nov;236(5):583-92 [12409664.001]
  • [Cites] Arch Surg. 1991 Oct;126(10):1205-10; discussion 1210-2 [1681794.001]
  • [Cites] Ann Surg. 2005 Dec;242(6):781-8, discussion 788-90 [16327488.001]
  • [Cites] Surgery. 2002 Jan;131(1):6-15 [11812957.001]
  • [Cites] World J Surg. 2006 Jul;30(7):1321-8 [16794906.001]
  • [Cites] Ann Thorac Surg. 2003 Feb;75(2):337-41 [12607635.001]
  • [Cites] Can J Surg. 1985 May;28(3):207-11 [3995416.001]
  • [Cites] Ann Surg. 2006 May;243(5):571-6; discussion 576-8 [16632990.001]
  • [Cites] ANZ J Surg. 2005 Jul;75(7):520-3 [15972035.001]
  • [Cites] Am J Surg. 1995 Jan;169(1):65-9; discussion 69-70 [7818000.001]
  • [Cites] Ann Surg. 2005 Oct;242(4):540-4; discussion 544-7 [16192814.001]
  • [Cites] Ann Surg. 2005 Apr;241(4):591-8 [15798460.001]
  • [Cites] Ann Surg. 1999 Mar;229(3):393-400 [10077052.001]
  • [Cites] Surgery. 2005 Jul;138(1):8-13 [16003309.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Aug;287(2):G315-9 [15246966.001]
  • (PMID = 17588191.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Turculeanu A, Avrămescu C, Bălăşoiu M, Pleşea E, Simionescu C, Popescu CF: Immuno-histopathological correlations in exocrine pancreatic cancer. Rom J Morphol Embryol; 2005;46(2):137-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immuno-histopathological correlations in exocrine pancreatic cancer.
  • OBJECTIVE: Study of CA19-9 antigen from the immunological point of view, at the patients with pancreatic cancer, and his relation with the histopathological aspects.
  • MATERIAL AND METHOD: The determinations have been done at the time of the diagnosis and after the treatment of the patients with pancreatic cancer (25).
  • RESULTS: The values of the CA19-9 marker have been increased at the time of the diagnosis either in pancreatic cancer of the head and mid.
  • At the moment of the diagnosis the CA19-9 marker has higher values (150-400 U/ml) in cancer of the pancreatic body than in cancer of the head of the pancreas (40-200 U/ml).
  • Correlating the size of the tumor with the value of the CA19-9 marker in the case of pancreatic cancer we have been shown the highest serum values (300-400 U/ml) at patients whose tumor was 3 cm bigger.
  • The highest values of the CA 19-9 marker were found in cases of mid pancreas adenocarcinoma.
  • CONCLUSION: CA19-9 marker values higher than normal cause problems to digestive cancer (especially pancreatic).
  • The high values of CA 19-9 suggest an adenocarcinoma.
  • [MeSH-major] CA-19-9 Antigen / analysis. Pancreatic Neoplasms / immunology. Pancreatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16287000.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen
  •  go-up   go-down


75. Longnecker DS, Adsay NV, Fernandez-del Castillo C, Hruban RH, Kasugai T, Klimstra DS, Klöppel G, Lüttges J, Memoli VA, Tosteson TD, Yanagisawa A, Wilentz R, Zamboni G: Histopathological diagnosis of pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms: interobserver agreement. Pancreas; 2005 Nov;31(4):344-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathological diagnosis of pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms: interobserver agreement.
  • OBJECTIVES: The goal of this study was to evaluate the consistency of distinction between pancreatic intraepithelial neoplasia (PanIN) and intraductal papillary-mucinous neoplasms (IPMN) and the hypothesis that guidelines for their distinction might be inadequate.
  • METHODS: A group of 93 pancreas specimens from surgical resections or autopsies that contained lesions consistent with histopathological diagnoses of PanIN-1A, PanIN-1B, PanIN-2, or IPMN (adenoma or borderline) was collected.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16258368.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA023108; United States / NCI NIH HHS / CA / CA023108; United States / NCI NIH HHS / CA / P50 CA62924
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


76. André T, Wislez M, Goncalves A, de La Motte Rouge T, Blay JY, Massard C, Bay JO, comité de rédaction du Bulletin du Cancer: [Following communications made at American Society of Clinical Oncology 2010, what will change our practice? The point of view of the editorial board of Bulletin du Cancer]. Bull Cancer; 2010 Dec;97(12):1551-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Following communications made at American Society of Clinical Oncology 2010, what will change our practice? The point of view of the editorial board of Bulletin du Cancer].
  • [Transliterated title] Suite aux communications faites au congrès de l'American Society of Clinical Oncology 2010, qu'est ce qui va changer nos pratiques ? Le point de vue du comité de rédaction du Bulletin du cancer.
  • The congress of Asco made the object of numerous summaries of congress made in the heat of the moment and the Bulletin du Cancer decided to ask to his editorial board, a digested summary, at distance of the congress, to try to sum up the data of the congress which are going to change practice.
  • The identification of the gene of fusion EML4-ALK in lung adenocarcinoma, and its inhibition by the crizotinib, constitute a considerable progress for 5% of patients with this disease.
  • In metastatic adenocarcinoma of the pancreas, there is finally an alternative to gemcitabine with the Folfirinox regimen, with an improvement of overall survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21220230.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


77. Rosemurgy A, Luzardo G, Cooper J, Bowers C, Zervos E, Bloomston M, Al-Saadi S, Carroll R, Chheda H, Carey L, Goldin S, Grundy S, Kudryk B, Zwiebel B, Black T, Briggs J, Chervenick P: 32P as an adjunct to standard therapy for locally advanced unresectable pancreatic cancer: a randomized trial. J Gastrointest Surg; 2008 Apr;12(4):682-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 32P as an adjunct to standard therapy for locally advanced unresectable pancreatic cancer: a randomized trial.
  • This prospective randomized trial was undertaken to determine the added efficacy of (32)P in treating locally advanced unresectable pancreatic cancer.
  • Thirty patients with biopsy proven locally advanced unresectable adenocarcinoma of the pancreas were assessable after receiving 5-fluorouracil and radiation therapy with or without (32)P, followed by gemcitabine.
  • Intratumoral (32)P was associated with more serious adverse events and did not improve survival for locally advanced unresectable pancreatic cancer.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Pancreatic Neoplasms / radiotherapy. Phosphorus Radioisotopes / therapeutic use

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Acad Med Singapore. 1996 May;25(3):347-51 [8876899.001]
  • [Cites] Nucl Med Biol. 1996 Oct;23 (7):907-10 [8971858.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Nov;17(5):931-5 [2808054.001]
  • [Cites] J Gastrointest Surg. 2003 Sep-Oct;7(6):766-72 [13129554.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Dec 1;36(5):1117-26 [8985034.001]
  • [Cites] Semin Oncol. 2005 Dec;32(6 Suppl 9):S33-6 [16399428.001]
  • [Cites] Strahlenther Onkol. 1998 Mar;174(3):133-41 [9524622.001]
  • [Cites] Cancer. 1980 Feb 15;45(4):709-14 [6244074.001]
  • [Cites] Cancer. 1997 Dec 15;80(12 Suppl):2743-8 [9406733.001]
  • [Cites] J Am Coll Surg. 2004 May;198(5):722-31 [15110805.001]
  • [Cites] Am Fam Physician. 2006 Feb 1;73(3):485-92 [16477897.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Oct 15;30(3):715-20 [7928505.001]
  • [Cites] Cancer. 1999 Feb 15;85(4):980-7 [10091778.001]
  • (PMID = 18266048.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Phosphorus Radioisotopes; U3P01618RT / Fluorouracil
  •  go-up   go-down


78. McWilliams RR, Bamlet WR, Cunningham JM, Goode EL, de Andrade M, Boardman LA, Petersen GM: Polymorphisms in DNA repair genes, smoking, and pancreatic adenocarcinoma risk. Cancer Res; 2008 Jun 15;68(12):4928-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms in DNA repair genes, smoking, and pancreatic adenocarcinoma risk.
  • We performed a clinic-based, case-control study comprising 481 consecutive patients with confirmed pancreatic adenocarcinoma and 625 healthy controls.
  • Carriers of one or two XPF/ERCC4 minor alleles at R415Q had decreased risk of pancreatic adenocarcinoma compared with those who had two major alleles [odds ratio (OR), 0.59; 95% confidence interval (95% CI), 0.40-0.85].
  • Minor alleles in DNA repair genes XPF/ERCC4 and XPD/ERCC2 were associated with altered risk for pancreatic cancer.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMC Bioinformatics. 2006;7:166 [16551372.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Aug;10(8):911-2 [11489761.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9420-7 [17018596.001]
  • [Cites] Wei Sheng Yan Jiu. 2006 Sep;35(5):534-6 [17086695.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2006;7:61-80 [16824020.001]
  • [Cites] Cancer Lett. 2007 Jan 8;245(1-2):61-8 [16458430.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Feb;16(2):342-6 [17301269.001]
  • [Cites] Mutat Res. 2000 Apr;462(2-3):149-58 [10767626.001]
  • [Cites] FEBS Lett. 2000 Jun 30;476(1-2):73-7 [10878254.001]
  • [Cites] Cancer Res. 2000 Oct 15;60(20):5612-6 [11059748.001]
  • [Cites] Teratog Carcinog Mutagen. 2001;21(1):7-25 [11135318.001]
  • [Cites] Carcinogenesis. 2001 Sep;22(9):1437-45 [11532866.001]
  • [Cites] Am J Hum Genet. 2002 Feb;70(2):425-34 [11791212.001]
  • [Cites] Cancer Res. 2002 Mar 1;62(5):1377-81 [11888908.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Apr;11(4):409-12 [11927502.001]
  • [Cites] Cancer Res. 2002 Apr 15;62(8):2253-7 [11956079.001]
  • [Cites] Am J Hum Genet. 2002 Jul;71(1):116-23 [12022038.001]
  • [Cites] Biotechniques. 2002 Jun;Suppl:70-2, 74, 76-7 [12083401.001]
  • [Cites] Cancer Res. 2002 Aug 15;62(16):4630-6 [12183419.001]
  • [Cites] J Natl Cancer Inst. 2002 Sep 18;94(18):1358-65 [12237281.001]
  • [Cites] Oncogene. 2002 Oct 21;21(48):7435-51 [12379884.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1513-30 [12496039.001]
  • [Cites] Nat Genet. 2003 Feb;33(2):177-82 [12524541.001]
  • [Cites] Hum Hered. 2003;55(1):56-65 [12890927.001]
  • [Cites] Am J Epidemiol. 2003 Sep 1;158(5):432-41 [12936898.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Nov;12(11 Pt 1):1200-4 [14652281.001]
  • [Cites] Genomics. 2004 Jun;83(6):970-9 [15177551.001]
  • [Cites] Epidemiology. 1990 Jan;1(1):43-6 [2081237.001]
  • [Cites] Ann Genet. 1991;34(3-4):143-50 [1809220.001]
  • [Cites] Arch Dermatol. 1994 Aug;130(8):1018-21 [8053698.001]
  • [Cites] Trends Biochem Sci. 1995 Oct;20(10):391-7 [8533150.001]
  • [Cites] Mol Cell Biol. 1997 Feb;17(2):564-70 [9001209.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] BMJ. 1998 Apr 18;316(7139):1236-8 [9553006.001]
  • [Cites] Carcinogenesis. 1998 Jul;19(7):1239-46 [9683183.001]
  • [Cites] J Natl Cancer Inst. 1999 Aug 4;91(15):1310-6 [10433620.001]
  • [Cites] Annu Rev Genet. 2004;38:445-76 [15568983.001]
  • [Cites] DNA Repair (Amst). 2005 Sep 28;4(10):1068-74 [16054878.001]
  • [Cites] Gut. 2005 Nov;54(11):1661-2 [16227367.001]
  • [Cites] Am J Epidemiol. 2005 Nov 15;162(10):925-42 [16221808.001]
  • [Cites] Carcinogenesis. 2006 Mar;27(3):610-8 [16258177.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1354-7 [11245433.001]
  • [Cites] Carcinogenesis. 2001 Apr;22(4):593-7 [11285194.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3321-5 [11309287.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Aug;8(8):669-74 [10744126.001]
  • [Cites] Genome Res. 2001 May;11(5):863-74 [11337480.001]
  • [Cites] Cancer Detect Prev. 2006;30(3):284-91 [16844323.001]
  • (PMID = 18544627.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K07 CA116303-03; United States / NCI NIH HHS / CA / K07 CA116303; United States / NCI NIH HHS / CA / CA116303-03; United States / NCI NIH HHS / CA / P50 CA102701; United States / NCI NIH HHS / CA / CA102701-06; United States / NCI NIH HHS / CA / P50 CA102701-06; United States / NCI NIH HHS / CA / R01 CA97075; United States / NCI NIH HHS / CA / R01 CA097075
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins
  • [Other-IDs] NLM/ NIHMS90860; NLM/ PMC2652067
  •  go-up   go-down


79. Duxbury MS, Whang EE: RRM2 induces NF-kappaB-dependent MMP-9 activation and enhances cellular invasiveness. Biochem Biophys Res Commun; 2007 Mar 2;354(1):190-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We examined the effect of RRM2 overexpression on pancreatic adenocarcinoma cellular invasiveness and nuclear factor-kappaB (NF-kappaB) transcription factor activity.
  • RRM2 overexpression increases pancreatic adenocarcinoma cellular invasiveness and MMP-9 expression in a NF-kappaB-dependent manner.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Matrix Metalloproteinase 9 / metabolism. NF-kappa B / metabolism. Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / pathology. Ribonucleoside Diphosphate Reductase / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Addgene Non-profit plasmid repository. clones/clone libraries - Get Article's Plasmids - Addgene (subscription/membership/fee required).
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • eagle-i research resources. PMID 17222798 (Special Collections) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17222798.001).
  • [ISSN] 0006-291X
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA114103
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NF-kappa B; EC 1.17.4.- / ribonucleotide reductase M2; EC 1.17.4.1 / Ribonucleoside Diphosphate Reductase; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


80. Brevet M, Fucks D, Chatelain D, Regimbeau JM, Delcenserie R, Sevestre H, Ouadid-Ahidouch H: Deregulation of 2 potassium channels in pancreas adenocarcinomas: implication of KV1.3 gene promoter methylation. Pancreas; 2009 Aug;38(6):649-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deregulation of 2 potassium channels in pancreas adenocarcinomas: implication of KV1.3 gene promoter methylation.
  • OBJECTIVES: The aim of this study was to examine expression of 2 potassium (K) channels in pancreatic adenocarcinoma.
  • METHODS: The immunohistochemical and mRNA expression of GIRK1 (G-protein inwardly rectifying K channel 1) and KV1.3 channel (voltage-dependent K channel) was studied in 55 and 18 adenocarcinomas and 33 and 8 normal pancreas specimens, respectively.
  • The methylation status of KV1.3 promoter was studied by methyl-specific polymerase chain reaction in 33 pancreatic adenocarcinomas.
  • RESULTS: GIRK1 was highly expressed in 80% (44/55) of adenocarcinoma samples versus 57.6% (19/33) of normal samples (P=0.03), as confirmed by reverse transcriptase-polymerase chain reaction results (P=0.007).
  • KV1.3 expression was decreased in pancreatic adenocarcinomas compared with normal tissue (7.3% vs 39.4%; P=0.0005).
  • CONCLUSION: This is the first report of deregulation of 2 K channels in pancreatic adenocarcinoma.
  • GIRK1 was highly expressed in pancreatic adenocarcinomas, corresponding to its role in cell proliferation.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. G Protein-Coupled Inwardly-Rectifying Potassium Channels / genetics. G Protein-Coupled Inwardly-Rectifying Potassium Channels / metabolism. Kv1.3 Potassium Channel / genetics. Kv1.3 Potassium Channel / metabolism. Pancreatic Neoplasms / genetics. Pancreatic Neoplasms / metabolism. Promoter Regions, Genetic

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19465885.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA, Neoplasm; 0 / G Protein-Coupled Inwardly-Rectifying Potassium Channels; 0 / Kv1.3 Potassium Channel; 0 / RNA, Messenger
  •  go-up   go-down


81. Deshpande V, Mino-Kenudson M, Brugge WR, Pitman MB, Fernandez-del Castillo C, Warshaw AL, Lauwers GY: Endoscopic ultrasound guided fine needle aspiration biopsy of autoimmune pancreatitis: diagnostic criteria and pitfalls. Am J Surg Pathol; 2005 Nov;29(11):1464-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Autoimmune pancreatitis (AIP) is a benign inflammatory disease of the pancreas that mimics pancreatic malignancy both clinically and radiologically.
  • We compared these to a cohort of EUS-guided aspirates from ductal carcinoma of the pancreas (n = 16) and chronic pancreatitis, not otherwise specified (NOS) (n = 19).
  • There were three false-positive cytologic diagnoses, an adenocarcinoma, a solid-pseudopapillary tumor and a mucinous neoplasm.
  • Stromal fragments with embedded lymphocytes (greater than 30 per 60x) were seen in 37.5% of AIP cases and only rarely with adenocarcinoma (12.5%) and pancreatitis, NOS (0%).
  • The presence of stromal fragments of high cellularity with a lymphoid infiltrate in conjunction with clinical and radiology findings could potentially both establish a diagnosis of AIP and exclude carcinoma, thus preventing pancreatic resection.
  • [MeSH-major] Adenocarcinoma / diagnosis. Autoimmune Diseases / diagnosis. Biopsy, Fine-Needle / methods. Endosonography. Pancreatic Neoplasms / diagnosis. Pancreatitis / diagnosis


82. Ohno E, Hirooka Y, Itoh A, Ishigami M, Katano Y, Ohmiya N, Niwa Y, Goto H: Intraductal papillary mucinous neoplasms of the pancreas: differentiation of malignant and benign tumors by endoscopic ultrasound findings of mural nodules. Ann Surg; 2009 Apr;249(4):628-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary mucinous neoplasms of the pancreas: differentiation of malignant and benign tumors by endoscopic ultrasound findings of mural nodules.
  • The diagnosis of IPMNs with types III or IV mural nodule as malignant resulted in a sensitivity of 60%, specificity of 92.9%, and accuracy of 75.9%.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Pancreatic Ductal / ultrasonography. Endosonography / methods. Neoplasm Invasiveness / pathology. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / ultrasonography
  • [MeSH-minor] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / ultrasonography. Aged. Aged, 80 and over. Analysis of Variance. Biopsy, Fine-Needle. Cohort Studies. Confidence Intervals. Contrast Media. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Logistic Models. Male. Mucous Membrane / pathology. Mucous Membrane / ultrasonography. Multivariate Analysis. Neoplasm Staging. Odds Ratio. Probability. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19300203.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


83. Bhardwaj A, Marsh WL Jr, Nash JW, Barbacioru CC, Jones S, Frankel WL: Double immunohistochemical staining with MUC4/p53 is useful in the distinction of pancreatic adenocarcinoma from chronic pancreatitis: a tissue microarray-based study. Arch Pathol Lab Med; 2007 Apr;131(4):556-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Double immunohistochemical staining with MUC4/p53 is useful in the distinction of pancreatic adenocarcinoma from chronic pancreatitis: a tissue microarray-based study.
  • CONTEXT: Immunohistochemical stains have been used for the distinction of pancreatic adenocarcinoma from chronic pancreatitis.
  • OBJECTIVE: To determine if a double stain for MUC/p53 improved specificity and sensitivity for distinction of pancreatic adenocarcinoma from chronic pancreatitis by comparing maspin, mucin 4 (MUC4), p53, Smad4, and the double stain MUC4/p53.
  • DESIGN: Seventy-four pancreatic adenocarcinomas and 19 chronic pancreatitis cases were retrieved from archival files.
  • RESULTS: The sensitivity for distinction of pancreatic adenocarcinoma from chronic pancreatitis with maspin, MUC4, p53, and Smad4 was 90%, 77%, 60%, and 63%, respectively; the specificity was 67%, 78%, 88%, and 88%, respectively.
  • CONCLUSION: The double immunohistochemical stain for MUC4/p53 can be a useful diagnostic tool in conjunction with the hematoxylin-eosin-stained section for pancreatic adenocarcinoma, particularly when limited tumor is available for multiple stains.
  • [MeSH-major] Adenocarcinoma / diagnosis. Mucins / metabolism. Pancreatic Neoplasms / diagnosis. Pancreatitis, Chronic / diagnosis. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Immunohistochemistry. Mucin-4. Sensitivity and Specificity. Serpins / metabolism. Smad4 Protein / metabolism. Tissue Array Analysis

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17425384.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MUC4 protein, human; 0 / Mucin-4; 0 / Mucins; 0 / SERPIN-B5; 0 / Serpins; 0 / Smad4 Protein; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


84. Beyer-Enke SA, Hocke M, Ignee A, Braden B, Dietrich CF: Contrast enhanced transabdominal ultrasound in the characterisation of pancreatic lesions with cystic appearance. JOP; 2010;11(5):427-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Contrast enhanced transabdominal ultrasound in the characterisation of pancreatic lesions with cystic appearance.
  • CONTEXT: Contrast enhanced ultrasound (CEUS) has been established for detection and characterisation of liver tumours and differential diagnosis of solid pancreatic lesions.
  • The role of transabdominal CEUS in cystic pancreatic disease is less obvious.
  • OBJECTIVE: We prospectively evaluated CEUS for characterization of undetermined cystic pancreatic lesions with respect to the differential diagnosis of pseudocysts and cystic neoplasia and differentiation between benign and malignant disease (gold standard: histology or cytology).
  • MAIN OUTCOME MEASURES: Conventional B-mode (criteria: solid nodules, septae), and contrast enhancing features of cystic pancreatic lesions (microperfusion of solid nodules) were analysed.
  • CONCLUSION: CEUS improves the differentiation between pseudocysts and pancreatic neoplasia in comparison to the conventional B-mode imaging.
  • The microvascularisation visualised using CEUS even in small nodules (with or without septae) associated with cystic lesions is an indicator for cystic pancreatic neoplasia.
  • [MeSH-major] Abdomen / ultrasonography. Adenocarcinoma / ultrasonography. Contrast Media. Pancreatic Cyst / ultrasonography. Pancreatic Neoplasms / ultrasonography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Image Enhancement / methods. Liver Neoplasms / ultrasonography. Male. Middle Aged. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20818109.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


85. Berkson BM, Rubin DM, Berkson AJ: Revisiting the ALA/N (alpha-lipoic acid/low-dose naltrexone) protocol for people with metastatic and nonmetastatic pancreatic cancer: a report of 3 new cases. Integr Cancer Ther; 2009 Dec;8(4):416-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Revisiting the ALA/N (alpha-lipoic acid/low-dose naltrexone) protocol for people with metastatic and nonmetastatic pancreatic cancer: a report of 3 new cases.
  • The authors, in a previous article, described the long-term survival of a man with pancreatic cancer and metastases to the liver, treated with intravenous alpha-lipoic acid and oral low-dose naltrexone (ALA/N) without any adverse effects.
  • Three additional pancreatic cancer case studies are presented in this article.
  • At the time of this writing, the first patient, GB, is alive and well 39 months after presenting with adenocarcinoma of the pancreas with metastases to the liver.
  • The second patient, JK, who presented to the clinic with the same diagnosis was treated with the ALA/N protocol and after 5 months of therapy, PET scan demonstrated no evidence of disease.
  • The third patient, RC, in addition to his pancreatic cancer with liver and retroperitoneal metastases, has a history of B-cell lymphoma and prostate adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liver Neoplasms / drug therapy. Pancreatic Neoplasms / drug therapy


86. Zhang YJ, Hu XG, Jin G, Shao CH, He TL, Li G, Jing W, Song B: [The role of full length superior mesenteric artery isolation in extended pancreaticoduodenectomy in the treatment of ductal adenocarcinoma of the pancreas in the uncinate process]. Zhonghua Wai Ke Za Zhi; 2009 Nov 1;47(21):1627-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The role of full length superior mesenteric artery isolation in extended pancreaticoduodenectomy in the treatment of ductal adenocarcinoma of the pancreas in the uncinate process].
  • OBJECTIVE: To improve the prognosis and safety of extended pancreaticoduodenectomy for patients with pancreatic cancer in the uncinate process of pancreas.
  • METHODS: From January 2004 to March 2008, 26 extended pancreaticoduodenectomies with full length superior mesenteric artery (SMA) isolation and mesentery root resection were performed for the ductal adenocarcinomas in the uncinate process of pancreas.
  • [MeSH-major] Mesenteric Artery, Superior / surgery. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy / methods

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20137396.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


87. Teke Z, Zengin NI, Atalay F, Karaman K, Demirbag AE, Akdogan M: A tumor-like lesion mimicking mucinous (colloid) carcinoma in heterotopic pancreas of the prepyloric antrum: a formidable challenge for frozen examination. JOP; 2010;11(3):237-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A tumor-like lesion mimicking mucinous (colloid) carcinoma in heterotopic pancreas of the prepyloric antrum: a formidable challenge for frozen examination.
  • CONTEXT: Heterotopic pancreas is defined as the presence of pancreatic tissue, outside its usual location, which lacks anatomical and vascular continuity with the pancreas proper.
  • Despite the development of modern diagnostic procedures, it is still difficult to differentiate heterotopic pancreas from benign or malignant tumors and other tumor-like lesions.
  • Frozen examination of mucinous lesions arising from heterotopic pancreas may represent a diagnostic problem.
  • CASE REPORT: We report a tumor-like lesion mimicking a mucinous (colloid) carcinoma arising in heterotopic pancreatic tissue in the prepyloric antrum of a 56-year-old woman which was found incidentally during an elective laparoscopic cholecystectomy for cholelithiasis.
  • The tumor was treated by wedge resection and, in the frozen section examination, there were pancreatic ducts in the proper muscle layer, pancreatic acini with islets of Langerhans under the serosal surface and mucinous lakes close to the heterotopic pancreatic tissue and to a peripheral nerve.
  • Such confusion is more likely to occur if the tissue sample is selective or limited, and the presence of pancreatic tissue cannot be verified.
  • Therefore, we believe that a choice of local excision, wedge resection or more extensive eradication be determined only after intraoperative, pathological confirmation of the complete and accurate diagnosis.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Choristoma / pathology. Pancreas. Pancreatic Neoplasms / pathology. Stomach Diseases / pathology
  • [MeSH-minor] Diagnosis, Differential. Female. Frozen Sections. Humans. Middle Aged. Pyloric Antrum / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20442519.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


88. Duxbury MS, Ito H, Benoit E, Waseem T, Ashley SW, Whang EE: RNA interference demonstrates a novel role for integrin-linked kinase as a determinant of pancreatic adenocarcinoma cell gemcitabine chemoresistance. Clin Cancer Res; 2005 May 1;11(9):3433-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RNA interference demonstrates a novel role for integrin-linked kinase as a determinant of pancreatic adenocarcinoma cell gemcitabine chemoresistance.
  • We examined the role of ILK in determining pancreatic adenocarcinoma cellular chemoresistance to the nucleoside analogue gemcitabine.
  • Levels of ILK expression affect gemcitabine chemoresistance in pancreatic adenocarcinoma cells.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. L-SERINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2000 Sep 7;19(38):4319-27 [10980607.001]
  • [Cites] Br J Cancer. 2003 Jun 2;88(11):1755-62 [12771992.001]
  • [Cites] J Cell Biol. 2000 Oct 30;151(3):483-94 [11062251.001]
  • [Cites] Oncogene. 2000 Nov 16;19(48):5444-52 [11114721.001]
  • [Cites] Oncogene. 2001 Jan 4;20(1):133-40 [11244511.001]
  • [Cites] Leuk Lymphoma. 2001 Feb;40(5-6):631-45 [11426535.001]
  • [Cites] Leukemia. 2001 Aug;15(8):1232-9 [11480565.001]
  • [Cites] Oncogene. 2001 Sep 27;20(43):6250-7 [11593435.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):3269-75 [11595724.001]
  • [Cites] Mol Cancer Ther. 2002 Oct;1(12):989-97 [12481421.001]
  • [Cites] EMBO Rep. 2003 Apr;4(4):432-8 [12671688.001]
  • [Cites] Genes Dev. 2003 Apr 1;17(7):926-40 [12670870.001]
  • [Cites] Mol Cell Biol. 1999 Nov;19(11):7420-7 [10523630.001]
  • [Cites] Br J Cancer. 2003 May 6;88(9):1470-9 [12778079.001]
  • [Cites] J Biol Chem. 2003 Jun 20;278(25):22374-8 [12686550.001]
  • [Cites] Br J Cancer. 2003 Jul 21;89(2):391-7 [12865934.001]
  • [Cites] Int J Mol Med. 2003 Nov;12(5):693-700 [14532995.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Nov 21;311(3):786-92 [14623342.001]
  • [Cites] Pancreas. 2004 Jan;28(1):38-44 [14707728.001]
  • [Cites] Cancer Cell. 2004 Jan;5(1):79-90 [14749128.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Feb 1;58(2):453-62 [14751515.001]
  • [Cites] Oncogene. 2004 Feb 26;23(8):1539-48 [14661056.001]
  • [Cites] Pancreas. 1990 May;5(3):267-77 [2111548.001]
  • [Cites] Nature. 1996 Jan 4;379(6560):91-6 [8538749.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] Curr Opin Oncol. 1997 Nov;9(6):549-56 [9370076.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4374-9 [9539744.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 15;95(19):11211-6 [9736715.001]
  • [Cites] Science. 1998 Nov 13;282(5392):1318-21 [9812896.001]
  • [Cites] Blood. 1999 Mar 1;93(5):1658-67 [10029595.001]
  • [Cites] Clin Cancer Res. 1999 Jun;5(6):1587-94 [10389948.001]
  • [Cites] Oncogene. 2000 Aug 3;19(33):3811-5 [10949937.001]
  • [Cites] Curr Opin Cell Biol. 2000 Apr;12(2):250-6 [10712922.001]
  • [Cites] Oncogene. 1999 Dec 23;18(56):8024-32 [10637513.001]
  • [Cites] Cancer Res. 2000 Oct 1;60(19):5451-5 [11034087.001]
  • (PMID = 15867245.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA114103-01; United States / NCI NIH HHS / CA / R01 CA114103-01
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Proto-Oncogene Proteins; 0 / RNA, Small Interfering; 0W860991D6 / Deoxycytidine; 452VLY9402 / Serine; B76N6SBZ8R / gemcitabine; EC 2.7.1.- / integrin-linked kinase; EC 2.7.11.- / Glycogen Synthase Kinases; EC 2.7.11.1 / AKT1 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.4.22.- / Caspases
  • [Other-IDs] NLM/ NIHMS84388; NLM/ PMC2734187
  •  go-up   go-down


89. Yantiss RK, Cosar E, Fischer AH: Use of IMP3 in identification of carcinoma in fine needle aspiration biopsies of pancreas. Acta Cytol; 2008 Mar-Apr;52(2):133-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of IMP3 in identification of carcinoma in fine needle aspiration biopsies of pancreas.
  • OBJECTIVE: To evaluate insulin-like growth factor-II mRNA binding protein 3 (IMP3), which is an oncofetal RNA-binding protein expressed in pancreatic carcinomas and detectable by immunohistochemistry, in diagnosis of pancreatic cancer.
  • STUDY DESIGN: We retrospectively identified 25 consecutive pancreatic endoscopic ultrasound-guided fine needle aspiration biopsies with available cell blocks, including 12 invasive pancreatic ductal carcinomas and 13 cases of chronic pancreatitis.
  • Cytoplasmic staining of the lesional cells and nonneoplastic pancreatic tissue was evaluated, and the intensity of staining was recorded as absent, weak, moderate or strong.
  • Nonneoplastic pancreatic tissues, present in 8 of 12 carcinomas and 13 cases of chronic pancreatitis, were negative for IMP3.
  • CONCLUSION: IMP3 is a promising new marker with high specificity and sensitivity for pancreatic adenocarcinoma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Biopsy, Fine-Needle. Carcinoma, Pancreatic Ductal / chemistry. Carcinoma, Pancreatic Ductal / pathology. Neoplasm Proteins / analysis. Pancreatic Neoplasms / chemistry. Pancreatic Neoplasms / pathology. RNA-Binding Proteins / analysis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18499984.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / IMP3 protein, human; 0 / Neoplasm Proteins; 0 / RNA-Binding Proteins
  •  go-up   go-down


90. Kalb B, Sarmiento JM, Kooby DA, Adsay NV, Martin DR: MR imaging of cystic lesions of the pancreas. Radiographics; 2009 Oct;29(6):1749-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MR imaging of cystic lesions of the pancreas.
  • Pancreatic cystic lesions are relatively common imaging findings and may be secondary to both benign and malignant disease processes.
  • Accurate characterization of the internal features of a cyst--including fluid, hemorrhage, septa, and enhancing soft-tissue components--is important to guide the differential diagnosis, and cross-sectional magnetic resonance (MR) imaging is the optimal modality for depicting these features.
  • Cystic lesions of the pancreas may be divided into two categories: (a) primary cystic lesions, which include pseudocysts, serous cystadenomas, various mucin-containing cysts (mucinous nonneoplastic cysts, mucinous cystadenomas, mucinous cystadenocarcinomas, intraductal papillary mucinous neoplasms), and lymphoepithelial cysts, and (b) various solid neoplasms undergoing cystic changes (ductal adenocarcinoma with cystic features, pseudopapillary tumors of the pancreas, and cystic neuroendocrine tumors).
  • Knowledge of the varied MR imaging appearances of pancreatic cystic lesions may help radiologists achieve greater specificity in diagnostic reporting.
  • [MeSH-major] Image Enhancement / methods. Magnetic Resonance Imaging / methods. Pancreatic Cyst / diagnosis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19959519.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Awadallah NS, Dehn D, Shah RJ, Russell Nash S, Chen YK, Ross D, Bentz JS, Shroyer KR: NQO1 expression in pancreatic cancer and its potential use as a biomarker. Appl Immunohistochem Mol Morphol; 2008 Jan;16(1):24-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NQO1 expression in pancreatic cancer and its potential use as a biomarker.
  • Pancreatic ductal adenocarcinoma (PDA) is rarely curable due to regional/metastatic spread at diagnosis.
  • Identification of molecular markers may enhance diagnosis and early detection of PDA.
  • For this study, we used 37 surgical resection cases: 24 PDAs and 13 benign pancreatic tissue specimens.
  • An additional 16 specimens from pancreatic endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) were included as a pilot series.
  • NQO1 staining was also observed in some benign ducts/cells; however, correlation of NQO1 expression with cellular morphology assessment minimizes the risk of false positive diagnosis.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18091324.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA51210
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; EC 1.6.5.2 / NAD(P)H Dehydrogenase (Quinone); EC 1.6.5.2 / NQO1 protein, human
  •  go-up   go-down


92. Lin F, Shi J, Liu H, Zhang J, Zhang PL, Wang HL, Yang XJ, Schuerch C: Immunohistochemical detection of the von Hippel-Lindau gene product (pVHL) in human tissues and tumors: a useful marker for metastatic renal cell carcinoma and clear cell carcinoma of the ovary and uterus. Am J Clin Pathol; 2008 Apr;129(4):592-605
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In normal tissues, positive immunoreactivity was observed only in renal tubules, exocrine pancreas, islets, and bile ducts.
  • These data indicate that this anti-pVHL antibody is a useful marker in assisting diagnosis of metastatic RCC and may serve as a diagnostic marker for clear cell carcinomas of the ovary and uterus.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Renal Cell / metabolism. Kidney Neoplasms / metabolism. Ovarian Neoplasms / metabolism. Uterine Neoplasms / metabolism. Von Hippel-Lindau Tumor Suppressor Protein / metabolism


93. Soliman AS, Bondy M, Webb CR, Schottenfeld D, Bonner J, El-Ghawalby N, Soultan A, Abdel-Wahab M, Fathy O, Ebidi G, Zhang Q, Greenson JK, Abbruzzese JL, Hamilton SR: Differing molecular pathology of pancreatic adenocarcinoma in Egyptian and United States patients. Int J Cancer; 2006 Sep 15;119(6):1455-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differing molecular pathology of pancreatic adenocarcinoma in Egyptian and United States patients.
  • Variations in genetic mutations in pancreatic carcinoma between different populations have not been studied extensively, especially in developing countries where pancreatic cancer is rare.
  • We studied the molecular pathology of 44 pancreatic carcinomas from patients residing in a heavily polluted region in the Nile River delta and compared the findings with tumors from 44 United States (US) patients.
  • Our study identifies that there are differences in the types of mutations found in tumors from pancreatic carcinoma patients in Egypt and the US, and suggests that environmental factors may explain these differences.
  • [MeSH-major] Adenocarcinoma / genetics. Cell Cycle Proteins / genetics. Genes, p53 / genetics. Genes, ras / genetics. Mutation / genetics. Nuclear Proteins / genetics. Pancreatic Neoplasms / genetics
  • [MeSH-minor] Carcinoma, Pancreatic Ductal / genetics. Carcinoma, Pancreatic Ductal / pathology. Case-Control Studies. DNA, Neoplasm / analysis. Egypt. Exons / genetics. Female. Humans. Male. Middle Aged. Polymerase Chain Reaction. United States

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16619252.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5 P30 CA46592; United States / NCI NIH HHS / CA / CA K07 090241; United States / NCI NIH HHS / CA / R03 CA099513-01
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / DNA, Neoplasm; 0 / GADD45A protein, human; 0 / Nuclear Proteins
  •  go-up   go-down


94. Salla C, Chatzipantelis P, Konstantinou P, Karoumpalis I, Sakellariou S, Pantazopoulou A, Manika Z: Endoscopic ultrasound-guided fine-needle aspiration cytology in the diagnosis of intraductal papillary mucinous neoplasms of the pancreas. A study of 8 cases. JOP; 2007;8(6):715-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic ultrasound-guided fine-needle aspiration cytology in the diagnosis of intraductal papillary mucinous neoplasms of the pancreas. A study of 8 cases.
  • CONTEXT: Intraductal papillary mucinous neoplasm (IPMN) is an increasingly recognized neoplasm of the pancreas, accounting for 5% of pancreatic neoplasms, it is considered difficult to diagnose by fine-needle aspiration (FNA) cytology.
  • OBJECTIVE: The aim of this study was to investigate the role of EUS-guided FNA cytology in the diagnosis of IPMN of the pancreas.
  • EUS/clinical findings, macroscopic/microscopic features of cell blocks and smears, and immunocytochemical stains accompanied by histopathologic diagnosis were recorded and studied.
  • RESULTS: EUS revealed hypoechoic masses in the head of pancreas (n=6) and in the body/tail (n=2), measuring from 16.6 to 35.8 mm.
  • In all cases, the hypoechoic mass had a distinctive distribution, involving the main pancreatic duct and/or the associated large branch ducts while intraductal nodules or multiple cysts were detected.
  • The histological diagnosis confirmed the FNA cytology diagnosis: 3 malignant IPMNs, 2 benign IPMNs and 3 borderline IPMNs.
  • Mucin 1 (MUC-1) was positive in 2 cases of malignant IPMN (histologically classified as null type ad intestinal type), mucin 2 (MUC-2) was positive in 3 cases (2 malignant both of the intestinal type, and 1 benign of the intestinal type I) and c-erbB2 was positive in 3 cases (2 benign - null and intestinal type - and 1 malignant null type).
  • CONCLUSIONS: The characteristic pre-operative EUS findings and cytomorphologic features, in addition to the immunocytochemical profile, were accurate indications and coincided with the final/post-operative histological diagnosis of IPMN.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / diagnosis. Adenocarcinoma, Papillary / pathology. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / pathology


95. Olivié D, Lepanto L, Billiard JS, Audet P, Lavallée JM: Predicting resectability of pancreatic head cancer with multi-detector CT. Surgical and pathologic correlation. JOP; 2007;8(6):753-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predicting resectability of pancreatic head cancer with multi-detector CT. Surgical and pathologic correlation.
  • CONTEXT: Computed tomography is widely used to pre-operatively evaluate patients with ductal carcinoma of the pancreas.
  • OBJECTIVE: To prospectively evaluate the ability of multi-detector computed tomography to predict resectability of pancreatic head cancer.
  • PATIENTS: Ninety-one consecutive patients (53 men, 38 women; mean age, 61 years) referred to our department with a diagnosis of cancer of the head of the pancreas underwent a preoperative contrast enhanced triphasic 16-slice multi-detector computed tomography.
  • RESULTS: Of the 91 patients evaluated, 25% had successful resection of pancreatic head carcinoma; while only 5% had a palliative procedure.
  • [MeSH-major] Adenocarcinoma / radiography. Adenocarcinoma / surgery. Pancreatic Neoplasms / radiography. Pancreatic Neoplasms / surgery. Tomography, Spiral Computed / methods

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17993727.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


96. Pezzilli R, Fabbri D, Imbrogno A: Does ablation technique utilized in the management of unresectable locally advanced pancreatic adenocarcinoma? Cancers (Basel); 2010;2(4):2098-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does ablation technique utilized in the management of unresectable locally advanced pancreatic adenocarcinoma?
  • Radiofrequency ablation in the management of advanced pancreatic cancer should be no longer utilized in patients with locally advanced or metastatic pancreatic adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24310354.001).
  • [ISSN] 2072-6694
  • [Journal-full-title] Cancers
  • [ISO-abbreviation] Cancers (Basel)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Other-IDs] NLM/ PMC3840461
  •  go-up   go-down


97. Freira S, Lourenço T, Cerqueira R, Tavares P, Pereira G, Barata D, Cabral J: [Hereditary pancreatitis in a child]. Acta Med Port; 2009 May-Jun;22(3):313-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The importance of a long term follow-up is highlighted, taking into consideration the risk of ductal pancreatic adenocarcinoma.


98. Ali S, Cohen C, Little JV, Sequeira JH, Mosunjac MB, Siddiqui MT: The utility of SMAD4 as a diagnostic immunohistochemical marker for pancreatic adenocarcinoma, and its expression in other solid tumors. Diagn Cytopathol; 2007 Oct;35(10):644-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The utility of SMAD4 as a diagnostic immunohistochemical marker for pancreatic adenocarcinoma, and its expression in other solid tumors.
  • Pancreatic adenocarcinoma is a genetic disease showing somatic mutations of multiple genes, including SMAD4.
  • SMAD4 is a tumor suppressor gene that is inactivated in a sub-set of pancreatic adenocarcinoma, either by the intragenic mutation of one allele in combination with the loss of the other allele or by homozygous deletion of both alleles.
  • This study examines SMAD4 expression in fine-needle aspiration cell blocks from patients with pancreatic adenocarcinoma, as well as a variety of human cancers, in order to assess its viability as a tumor marker.
  • A total of 100 patients with pancreatic adenocarcinoma, with diagnostic material from fine-needle aspiration cell blocks were selected for this study.
  • SMAD4 staining was nuclear and the results for tumor cell positivity for primary sites studied are as follows: Pancreas (80/100; 80%), endometrium (0/100; 0%), colon (0/100; 0%), ovary (3/100; 3%), lung (0/100; 0%), breast (2/100; 2%), and malignant melanoma (4/100; 4%).
  • This study suggests that SMAD4 is an important marker for confirming a diagnosis of pancreatic adenocarcinoma as a primary tumor, as well as when it presents as a metastatic tumor on small fine-needle aspirate samples.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / metabolism. Smad4 Protein / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17854080.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / SMAD4 protein, human; 0 / Smad4 Protein
  •  go-up   go-down


99. Venkatasubbarao K, Choudary A, Freeman JW: Farnesyl transferase inhibitor (R115777)-induced inhibition of STAT3(Tyr705) phosphorylation in human pancreatic cancer cell lines require extracellular signal-regulated kinases. Cancer Res; 2005 Apr 1;65(7):2861-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Farnesyl transferase inhibitor (R115777)-induced inhibition of STAT3(Tyr705) phosphorylation in human pancreatic cancer cell lines require extracellular signal-regulated kinases.
  • In this study, we report that R115777, a nonpeptidomimetic farnesyl transferase inhibitor, suppresses the growth of human pancreatic adenocarcinoma cell lines and that this growth inhibition is associated with modulation in the phosphorylation levels of signal transducers and activators of transcription 3 (STAT3) and extracellular signal-regulated kinases (ERK).
  • These observations suggest that R115777-induced growth inhibition is partly due to the prolonged activation of ERKs that mediates an inhibition of STAT3((Tyr705)) phosphorylation and an increase in the levels of p21(cip1/waf1) in human pancreatic adenocarcinoma cell lines.
  • [MeSH-major] Adenocarcinoma / drug therapy. Alkyl and Aryl Transferases / antagonists & inhibitors. DNA-Binding Proteins / metabolism. Extracellular Signal-Regulated MAP Kinases / metabolism. Pancreatic Neoplasms / drug therapy. Quinolones / pharmacology. Trans-Activators / metabolism


100. Enestvedt CK, Mayo SC, Diggs BS, Mori M, Austin DA, Shipley DK, Sheppard BC, Billingsley KG: Diagnostic laparoscopy for patients with potentially resectable pancreatic adenocarcinoma: is it cost-effective in the current era? J Gastrointest Surg; 2008 Jul;12(7):1177-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic laparoscopy for patients with potentially resectable pancreatic adenocarcinoma: is it cost-effective in the current era?
  • INTRODUCTION: For patients with potentially resectable pancreatic cancer, diagnostic laparoscopy may identify liver and peritoneal metastases that are difficult to detect with other staging modalities.
  • The aim of this study was to utilize a population-based pancreatic cancer database to assess the cost effectiveness of preoperative laparoscopy.
  • De-identified patient records were reviewed to determine the role and findings of laparoscopic exploration.
  • CONCLUSION: Cost analysis indicates that the case-specific or routine use of laparoscopy in pancreatic cancer does not add significantly to the overall expense of treatment and supports the use of laparoscopy in patients with known or suspected pancreatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Laparoscopy / economics. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Nov 1;89(9):1917-24 [11064348.001]
  • [Cites] Br J Surg. 2001 Mar;88(3):325-37 [11260096.001]
  • [Cites] J Am Coll Surg. 2001 Jun;192(6):768-76 [11400971.001]
  • [Cites] Oncology. 2006;70(1):71-80 [16465066.001]
  • [Cites] World J Surg. 2003 Oct;27(10):1075-84 [12925907.001]
  • [Cites] J Gastrointest Surg. 2007 Jan;11(1):36-42 [17390184.001]
  • [Cites] Gastrointest Endosc. 1999 Apr;49(4 Pt 1):498-503 [10202066.001]
  • [Cites] Am J Gastroenterol. 2000 Jul;95(7):1708-13 [10925972.001]
  • [Cites] Surg Endosc. 2001 Oct;15(10 ):1129-34 [11727085.001]
  • [Cites] J Gastrointest Surg. 2005 Dec;9(9):1286-92 [16332484.001]
  • [Cites] Ann Surg. 1997 May;225(5):621-33; discussion 633-6 [9193189.001]
  • [Cites] J Am Coll Surg. 1998 Jun;186(6):675-82 [9632157.001]
  • [Cites] Surg Endosc. 2005 May;19(5):638-42 [15776215.001]
  • [Cites] Ann Surg. 1996 Feb;223(2):134-40 [8597506.001]
  • [Cites] Ann Surg Oncol. 2001 Apr;8(3):249-53 [11314942.001]
  • [Cites] Ann Surg. 2002 Jan;235(1):1-7 [11753036.001]
  • [Cites] Am J Surg. 1996 May;171(5):533-7 [8651403.001]
  • [Cites] N Engl J Med. 1996 Aug 15;335(7):476-82 [8672153.001]
  • [Cites] J Am Coll Surg. 1998 Jan;186(1):35-40 [9449598.001]
  • [Cites] Arch Surg. 2000 Apr;135(4):409-14; discussion 414-5 [10768705.001]
  • [Cites] J Am Coll Surg. 1999 Jun;188(6):649-55; discussion 655-7 [10359358.001]
  • [Cites] Arch Pediatr Adolesc Med. 1999 Sep;153(9):965-8 [10482214.001]
  • [Cites] Ann Oncol. 2006 Feb;17(2):189-99 [16236756.001]
  • (PMID = 18470572.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement